

The Evolution of Neonatology

ALISTAIR G.S. PHILIP

Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, Palo Alto, CA 94304

ABSTRACT

In 1960, the terms “neonatology” and “neonatologist” were introduced. Thereafter, an increasing number of pediatricians devoted themselves to full-time neonatology. In 1975, the first examination of the Sub-Board of Neonatal-Perinatal Medicine of the American Board of Pediatrics and the first meeting of the Perinatal Section of the American Academy of Pediatrics were held. One of the most important factors that improved the care of the neonate was the miniaturization of blood samples needed to determine blood gases, serum electrolytes, glucose, calcium, bilirubin, and other biochemical measurements. Another factor was the ability to provide nutrition intravenously, and the third was the maintenance of normal body temperature. The management of respiratory distress syndrome improved with i.v. glucose and correction of metabolic acidosis, followed by assisted ventilation, continuous positive airway pressure, antenatal corticosteroid administration, and the introduction of exogenous surfactant. Pharmacologic manipulation of the ductus arteriosus, support of blood pressure, echocardiography, and changes in the management of persistent pulmonary hypertension, including the use of nitric oxide and extracorporeal membrane oxygenation, all have influenced the cardiopulmonary management of the neonate. Regionalization of neonatal care; changes in parent–infant interaction; and technological changes such as phototherapy, oxygen saturation monitors, and brain imaging techniques are among the important advances reviewed in this report. Most remarkable, a 1-kg infant who was born in 1960 had a mortality

risk of 95% but had a 95% probability of survival by 2000. However, errors in neonatology are acknowledged, and potential directions for the future are explored. (*Pediatr Res* 58: 799–815, 2005)

Abbreviations

AAP, American Academy of Pediatrics
BPD, bronchopulmonary dysplasia
CPAP, continuous positive airway pressure
ECMO, extracorporeal membrane oxygenation
ELBW, extremely low birth weight
HMD, hyaline membrane disease
iNO, inhaled nitric oxide
IUGR, intrauterine growth restriction
IVH, intraventricular hemorrhage
L/S, ratio of lecithin, phosphatidyl choline, to sphingomyelin
NICU, neonatal intensive care unit
PDA, patent ductus arteriosus
PEEP, positive end expiratory pressure
PPHN, persistent pulmonary hypertension of the newborn
PVH, periventricular hemorrhage
RDS, respiratory distress syndrome
ROP, retinopathy of prematurity
SIDS, sudden infant death syndrome
VLBW, very low birth weight
VON, Vermont-Oxford Network

“There is need for specialization in neonatal medicine. This applies to doctors and nurses as well as teaching and construction of hospitals. The specialist in neonatal diseases and the nurse intensively trained and expert in the management of delicate newborns will be commonplace ere long.”

J.W. Ballantyne, 1923 (1)

“In previous times the problems of the newborn child have been the province of the obstetrician, a field in which he has

taken comparatively little interest and to which he has contributed little. As pediatricians we have but scratched the surface.”

C.G. Grulee, 1939 (2)

The beginning of modern neonatology started ~50 y ago, although there were physicians who were interested in the welfare of the newborn infant earlier. The first edition of the booklet entitled “Standards and Recommendations for Hospital Care of Newborn Infants” was published by the Committee on Fetus and Newborn of the American Academy of Pediatrics (AAP) in 1948. Four years later, Virginia Apgar presented a paper to the anesthesia research societies about neonatal assessment in the delivery room (3) and helped focus attention on the newborn infant.

Much of what we know about the years before this has been recorded in two books written by pediatricians. The first was

Received July 23, 2004; accepted November 5, 2004.

Correspondence: Alistair G.S. Philip, M.D., F.R.C.P.E., Department of Pediatrics, Division of Neonatal and Developmental Medicine, Stanford University School of Medicine, 750 Welch Road, Suite 315, Palo Alto, CA 94304; e-mail: alistair.philip@stanford.edu.

DOI: 10.1203/01.PDR.0000151693.46655.66

by Thomas E. Cone, Jr., of Boston, who published his book in 1985 (4). A more concise version of Dr. Cone's thoughts can be found in the first of two small volumes published in 1983, which were widely distributed at the time but difficult to find now (5). The second was by Murdina M. Desmond, published in 1998 (6), the title of which reflects her own background.

Physicians who had an interest in the newborn were evident in the 19th century, but most were obstetricians. The idea that premature infants could be treated was probably introduced in the second half of the 19th century. At that time, considerable attention was devoted to accurate measurement of birth weight, to feeding, and to the use of incubators in France, Germany, and England.

In the mid-20th century, many pediatricians demonstrated an interest in the newborn; the primary responsibility for these infants passed from the obstetrician to the pediatrician. Several premature nurseries existed in the United States in the 1930s and 1940s, and books were written on care of the newborn, particularly the premature infant, such as those by Julius H. Hess, M.D. (7), Arthur H. Parmelee, Sr. (8), and Ethel C. Dunham (9) in the United States and V. Mary Crosse (10) in the United Kingdom. In Scandinavia, Arvo Ylppö, the Finnish pediatrician (1887–1992), spread the word about the physiology and pathology of the newborn, based on his studies in Berlin.

The work of Sir Joseph Barcroft in the United Kingdom brought new understanding of the fetus (11); and in the United States, Clement Smith published his book on the physiology of the newborn infant (12). Their work and that of their collaborators provided a solid basis for the development of evidence-based clinical care, even if the evidence was largely in nonhuman mammalian fetuses and neonates. It is appropriate to single out Dr. Julius Comroe at the Cardiovascular Research Institute in San Francisco and Dr. Geoffrey Dawes in Oxford, England (13), as key figures who fostered and promoted physiologic investigation of the fetus and neonate.

The term *neonatology* was coined in 1960 and is attributed to Alexander Schaffer, M.D., who used the term in the introduction to the first edition of his book (14). Also in the early 1960s, an important distinction was made between small infants who were born preterm (<38 wk gestation) and term infants who were small because of intrauterine growth restriction (IUGR). Previously, any infant whose birth weight was <2500 g was deemed to be premature.

Theoretical knowledge was advancing rapidly in this era, but it was not until the late 1960s and early 1970s that major changes in clinical care occurred. One of the most important advances was the miniaturizing of blood samples needed to do blood tests for management of clinical care, such as serum electrolytes, blood gases, bilirubin, and liver function tests (15). It was not until the second half of the 20th century that attitudes began to change. As noted by Nicholas Nelson, M.D., in 1983, "The fluid and electrolyte supports introduced by Usher and the respiratory supports introduced by Stahlman, Swyer, Tooley, James and others, not to mention the freer use of diagnostic catheters by cardiologists, all brought the sick premature newborn infant to his present state of respectability

as a patient to be cared for, rather than an object to be pitied" (16).

There are several key areas that provide the basis for the care of all neonates. I have put these into perspective and focus on some of the more important advances of the last 40 y or so that pertain to the preterm infant.

THERMOREGULATION

At this point, it is probably not necessary to detail the development of the modern incubator (17–19). Suffice it to say that at the end of the 19th century, infant and neonatal mortality was alarmingly high and temperature regulation improved survival. Tarnier and Budin, in Paris, emphasized the utility of the incubator, as did von Reuss, in Germany, but they acknowledged the work of others who preceded them. The first incubator was introduced in 1835 by Von Ruehl in St. Petersburg, Russia (20). In the United States, attention was drawn to the potential of incubators by the side-show displays of Martin Couney at a permanent exhibit at Coney Island, which closed in 1933, and at World's Fairs in Chicago and New York (the latter in 1939–1940) (17,18). Various incubators were designed and used in Europe and the United States, but it was not until the work of William Silverman, Richard Day, and colleagues at Columbia, New York, in the 1950s that the benefits of modifying body temperature were demonstrated. In one of the first randomized, controlled trials in neonatology, they were able to show that survival was better in preterm infants who were kept in incubators that were 4° warmer than in the control infants (21). Despite these results, it took several years before they were translated into routine care of preterm infants. (As a pediatric resident in the mid-1960s, I remember that it was considered normal for preterm infants to have lower body temperatures than term infants.)

Subsequently, the factors that affect the equation of heat loss *versus* heat production were elucidated (22). The importance of radiant heat loss led to the introduction of radiant warmers, both in the delivery room and in premature nurseries. It was also noted that an important component of heat production was the presence of brown fat (23). It was demonstrated that not all infants of low birth weight (LBW) were born preterm but might be small for gestational age or experience IUGR (24). Some were found to have difficulty maintaining their body temperature, largely because they lacked brown fat. Because other substrate was used to produce heat, they also developed low blood glucose levels. For different-sized infants, at different postnatal ages, a range of temperatures, called the neutral thermal environment (25), was found to minimize energy expenditure.

Another important advantage of the modern incubator is improved visibility. When clear plastic incubators were introduced in the late 1940s, "Nurses and doctors stared at the naked babies as if they were seeing them for the first time. Naked infants were examined more completely, observed more closely, and treated more actively than ever before" (18).

NUTRITION

Keeping infants warm is a basic necessity; so, too, is providing appropriate nutrition.

Infant formula. After the discovery of the chemical composition of milk in the 1890s, various percentages of protein, fat, and carbohydrate were used to prepare feeding, called “formula” feeds; the feeding that approximated human milk was introduced in the 1920s. Evaporated cow milk was the basic milk product used, to which was added carbohydrates such as Karo syrup, both for term and preterm infants. To supplement breast milk, DaFoe, in caring for the Dionne quintuplets, used a preparation of evaporated milk, water, and corn syrup, to which a few drops of rum were added (26).

The work of Levine and Gordon in the early 1940s documented that preterm infants who were fed formulas with increased protein, calcium, phosphorus, and sodium and decreased saturated fats grew more rapidly. However, high protein intake resulted in fluid retention, azotemia, and metabolic acidosis. The introduction of whey-predominant formulas for the preterm infant in the early 1980s resolved many of these problems (27).

Nevertheless, “breast is best” is the motto that most neonatologists promote today (28). The composition of human milk expressed by mothers who have delivered prematurely was found to differ from that produced at term and is more appropriate for preterm infants, even though supplements are required to increase caloric strength and protein, sodium, calcium, and phosphorus (29).

Techniques for providing nutrition. Until the preterm neonate became “a patient to be cared for,” attempts at providing adequate nutrition were limited. Gavage feeding using soft red rubber catheters was reported as early as 1851 by Marchant of Charenton, according to Budin (30), and polyethylene tubes were introduced in the 1950s (31).

The difficulty in preterm infants is the immaturity of the gastrointestinal tract, especially with immature motility patterns and delayed transit. Particularly, in the presence of edema and difficulties with respiration, many preterm infants in the United States were deprived of all nutrition and were frequently starved for up to 72 h or even longer. In hindsight, it is hard to understand the logic behind this approach. Many European physicians, especially Ylppö, were critical of the idea. Early feeding of preterm infants with breast milk was promoted in Oxford as early as 1964 (32). As difficulties with hypoglycemia and hyperbilirubinemia were better appreciated in these preterm infants, the need for the early provision of nutrition became more apparent in the United States (33).

Difficulties in providing enteral nutrition stimulated the introduction of i.v. feeding, a major advance. Another important advance was the development of microinfusion pumps, now able to deliver increments as small as 0.1 mL/h. This facilitated the accurate administration of i.v. fluids to extremely preterm infants.

Initially, peripheral venous nutrition was primarily in the form of glucose. Numerous investigators attempted to infuse protein hydrolysates to the preterm or postsurgical infant, but it was Dudrick and Wilmore who worked initially with labora-

tory animals in Rhoads’s Department and developed the basis by which high caloric i.v. preparations, with appropriate nitrogen concentrations, could be infused into large-caliber vessels (34,35).

These techniques were rapidly applied to the care of the low birth weight infant (36,37). At first, the protein was provided by casein or fibrin hydrolysates, but complications such as metabolic acidosis, hyperammonemia, and azotemia resulted. Newer amino acid preparations were developed, and these complications were almost completely eliminated (38). The addition of trace elements and vitamins enhanced the i.v. cocktail, and after a great deal of difficulty in identifying an appropriate i.v. lipid preparation, this, too, was added to the nutritional support of the preterm infant (39).

Initially, these preparations had to be infused into major veins and even the umbilical arteries. Peripherally inserted central venous catheters have been used with increasing frequency in recent years. Peripheral venous lines have also been used with lowered concentration of glucose (10–12%) for short-term nutritional support.

Over time, it was learned that there are limitations to the amount that can be tolerated, usually $4 \text{ g} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ of amino acid and $3.5 \text{ g} \cdot \text{kg}^{-1} \cdot \text{d}^{-1}$ of lipid (40,41). Currently, the major difficulties that we have with total parenteral nutrition in these infants is our inability to provide adequate calcium and phosphorus, and also the development of total parenteral nutrition-induced cholestasis.

Recently, trophic feeds (minimal enteral feeds) have been advocated for the very immature infant to enhance the more rapid development of gastrointestinal function. Early reports of the use of this technique have been associated with a decreased incidence of both cholestasis and nosocomial infections (42).

GROWTH

Growth norms. Several groups published growth curves to indicate the anticipated measurements for birth weight, length, and head circumference at various gestational ages. Some of these data were gathered at high altitude (43) and others at sea level (44) and allowed for the introduction of the concept of small-, appropriate-, and large-for-gestational-age infants (45).

Disordered fetal growth. The system of classification of neonates into small, appropriate, or large for gestational age was published in 1967, but the realization that some fetuses were either undergrown or overgrown came several years earlier. Farquhar in Scotland (46) and Gellis and Hsia (47) and Cornblath (48) in the United States had written about the overgrowth of infants of diabetic mothers and recognized that they were prone to a litany of problems, such as hypoglycemia, respiratory distress syndrome (RDS), hyperbilirubinemia, hypocalcemia, hypertrophic cardiomyopathy, etc., when mothers were poorly controlled.

Gruenwald (49) drew attention to the idea that undergrowth might be the result of placental insufficiency, and Warkany *et al.* (50) probably introduced the term “intrauterine growth retardation,” which recently was modified as “intrauterine growth restriction” because parents are frequently alarmed by the word “retardation.” Adding to the confusion are other terms

such as fetal malnutrition, dysmaturity, hypotrophy, and light or small for dates. This disorder has its own set of immediate problems, such as fetal distress, hypoglycemia, hyperviscosity, etc. but may also have life-long consequences on health, such as hypertension and diabetes; this is known as the “Barker hypothesis” (51). Although careful control of diabetic mothers during pregnancy has decreased the number of classical infants, the ability to affect the outcome of IUGR fetuses has been more limited, probably because of multifactorial cause.

Postmaturity. Before birth weight/gestational age classification was introduced, it was recognized that in addition to many premature infants, some were born postmature, usually >42 wk gestation, and were distinguishable by features such as meconium staining of the umbilicus and fingernails and deep creases on the feet. Stewart Clifford provided a detailed discussion of such infants (52). Like other dysmature infants, postmaturity was associated with problems linked to hypoxemia and undernutrition. Recently, obstetric management resulted in an aggressive approach to prevent postterm delivery (53).

RESPIRATORY SUPPORT

Oxygen. Until the mid-1960s, the primary support for respiratory function was the provision of supplementary oxygen. This simple therapy proved to have devastating consequences when the philosophy of “if a little is good, a lot should be better” was espoused and many preterm infants developed retrolental fibroplasia, now called retinopathy of prematurity (ROP).

In an era when it was difficult to measure oxygen tension in the blood, the only way to determine whether an infant was adequately oxygenated was to observe color. If the infant was cyanotic, then oxygen was administered to relieve cyanosis but often in concentrations that produced superoxygenation, it was later determined. Cyanosis in adults is usually clinically apparent when ~5 g/100 mL of deoxygenated (reduced) Hb is circulating. It was shown in neonates that cyanosis was evident when 3 to 4 g/100 mL of deoxygenated Hb was present (54).

The ability to measure arterial oxygen tension made a huge difference in our ability to manage oxygen therapy. Blood samples of ~2 mL were needed, but by the end of the 1960s, sample size was down to 0.5 mL and subsequently to 0.2–0.3 mL. Because of the association of ROP with the liberal use of oxygen, there was proscription of the use of 100% oxygen. Incubators of that era were designed so that no more than 40% oxygen could be delivered, unless a baffle on the back of the incubator were closed. When this was done, it literally raised a red flag to indicate that dangerous amounts of oxygen were used. The pendulum had swung the other way, and infants undoubtedly died because they were deprived of adequate amounts of oxygen (18).

The physiologic studies of Joseph Barcroft, Donald Barron, Clement Smith, John Lind, Geoffrey Dawes, and others showed that the fetal animal and, presumably, the human had a much lower circulating P_{O_2} than the human newborn. This had specific import for the infant who was born very preterm (<32 wk), because these infants would not have been exposed

to even normal levels of P_{O_2} had they remained *in utero*. The specific cause of ROP is probably multifactorial, but the generation of oxygen-free radicals almost certainly is contributory (55).

Resuscitation in the delivery room. It is now hard to appreciate the benign neglect that occurred in most delivery rooms in the world until the late 1950s. Earlier, Virginia Apgar had reported her scoring system and in 1958 (56) proposed that someone other than the delivering obstetrician or midwife should concern him- or herself with the infant or infants. She suggested that the infant should be evaluated using five parameters—heart rate, respiration, reflex activity, tone, and color—within the first minute, and, if necessary, intervention to improve the situation should occur before reevaluation of the infant at 5 min (56). Although the method has occasionally been questioned, it remains a very valuable tool in neonatal assessment around the world (57). It should be emphasized that Dr. Apgar never claimed that her score was predictive of long-term outcome, and it should not be used for this purpose.

Virginia Apgar may have been the first person to insert an umbilical artery catheter for the purpose of measuring arterial blood gases (58). This technique was certainly key and improved our ability to obtain better results with assisted ventilation.

During the past few years, the need for 100% oxygen in the delivery room has been questioned, because many infants can be resuscitated successfully in room air (59). This idea has not been universally accepted at the time of writing. What *has* been accepted is the role of bag-and-mask ventilation or endotracheal intubation and assisted ventilation when an infant fails to establish spontaneous respiration. Both of these techniques followed logically from evaluation of the Apgar scores and replaced other methods that were considered useful but that had marginal utility. When I graduated from medical school in Edinburgh, Scotland, in 1961, the approved method of resuscitation was intragastric oxygen. In Glasgow, hyperbaric oxygen was proposed for this purpose (60), although it sometimes took approximately half an hour to place the infant in the device!

One specific aspect of neonatal resuscitation is the approach to prevent meconium aspiration syndrome (61). Although not all cases can be prevented, suctioning of the oropharynx with the head on the perineum, followed by prophylactic endotracheal intubation and suctioning became an early example of obstetrician and pediatrician collaboration (62).

In the past 20 y, the establishment of a national resuscitation program in the United States codified neonatal resuscitation in a way that could be taught to thousands of physicians and nurses (63). The program has been exported to other countries, and although it has had wide acceptance and application, it may be replaced by more sophisticated methods in the future.

Despite the widespread improvement in neonatal resuscitation, intrapartum asphyxia continues to be a problem. It was hoped that the use of fetal heart rate monitoring and fetal scalp sampling, to evaluate fetal blood pH, would eliminate this concern, but it has not been the case. It was also assumed that careful fetal evaluation by the obstetrician would decrease the incidence of cerebral palsy. This has been shown to be a false

assumption, with few cases (maybe 15%) of cerebral palsy attributable to intrapartum events (64).

Intrapartum asphyxia was found usually to be the result of either poor uteroplacental blood flow (*e.g.* with hypertensive disorders) or a sudden hypoxemic event (*e.g.* prolapsed umbilical cord, acute placental abruption). The important studies of asphyxia in primates performed by Dr. William Windle and later by Ronald Meyers and Albert Brann deserve special mention. The situations above roughly equate to partial prolonged asphyxia or total acute asphyxia evaluated in the primate (65). Because of the poor outcomes after a prolonged asphyxial insult, methods to protect against such injury have been sought. Recently, this has stimulated attempts to decrease brain metabolism by using moderate systemic hypothermia or localized brain hypothermia. However, the window of opportunity for this therapy is open for only a short time (66).

Assisted ventilation. It was not until the mid-1960s that attempts were made to provide continuous respiratory support, using mechanical ventilation, for infants with severe respiratory disease. At that time, most preterm infants who died after several days were found to have histologic evidence of hyaline membranes in the lungs at postmortem examination. They were considered to have hyaline membrane disease (HMD). Mary Ellen Avery and Jere Mead showed in 1959 that this disorder was linked to a deficiency of surfactant in lung fluid (67). At approximately the same time, the alternative hypothesis was proposed that pulmonary hypoperfusion might be the determining factor in development of hyaline membranes (68).

Because HMD was the apparent cause of death of the infant son of President John F. Kennedy, research money became available to investigate the cause and support the management of the disorder. Not all infants with the disease died but often demonstrated spontaneous improvement after increasing severity of illness for 2 or 3 d. At approximately this time, Robert Usher, in Montreal, showed in a randomized, controlled trial that RDS mortality could be reduced by using a constant infusion of i.v. glucose and bicarbonate to minimize hyperkalemia and acidosis (69). In the 1960s, this was known as “the Usher regime.”

Portable x-ray machines became available and contributed to the more accurate assessment and aggressive management of respiratory disorders of the neonate. Earlier, infants were considered too sick to have an x-ray. Now, the machine came to the infant, instead of taking the infant to the machine.

A national consensus conference determined that the term RDS was probably more appropriate than HMD, because HMD was a pathologic diagnosis. However, this consensus was a small majority. Because of the uncertain cause, “idiopathic” was frequently placed before RDS (hence, IRDS).

In the mid-1960s, a group of investigators in several different centers began to adapt mechanical ventilators, used for adults, to assist ventilation of infants with RDS with the hope that they could be helped through the critical first days, until spontaneous resolution might occur. In the beginning, only the sickest infants were tried on assisted ventilation, with variable success. Many times it was possible to produce improvement for several days, only to have the infant succumb days later. In

the early days of mechanical ventilation, both positive-pressure ventilators and negative-pressure ventilators were used.

I was fortunate to spend 3 mo in 1969 at the Port Royal–Baudelocque Center in Paris, which was headed by Prof. Alex Minkowski. Early in my stay, I observed a conference on assisted ventilation, the proceedings of which were later published in *Biology of the Neonate* (the journal established by Prof. Minkowski as *Biologia Neonatorum*) (70). The big question was whether it was appropriate to continue to push forward with assisted ventilation in light of technical difficulties—the negative-pressure ventilator was almost impossible to use in infants who weighed <1500 g—and other complications such as bronchopulmonary dysplasia (BPD), which had already been described with positive-pressure ventilation (71). The answer now is obvious, but there was a good deal of soul searching at the time.

Two specific problems related to assisted ventilation deserve comment: BPD and pulmonary interstitial emphysema. BPD was first described in 1967 (71) and was sometimes called “respirator lung” (70). It was subsequently recognized that this was not exclusively oxygen toxicity but seemed to be caused by the combination of barotrauma (pressure), oxygen, and the duration of exposure of the immature lung to both (72). In the 1970s and 1980s, prolonged hospitalization as a result of the consequences of lung injury was common. Cystic change and marked hyperinflation were not uncommon and frequently led to cor pulmonale and death. Since the advent of surfactant treatment for RDS, BPD is a much more benign disorder. It is now commonly referred to as chronic lung disease of prematurity, with radiographic features that are much less dramatic but are accompanied by prolonged oxygen dependence (73). However, this is usually for several weeks beyond term gestation, whereas it was formerly for several months.

Before the introduction of surfactant therapy, assisted ventilation was frequently accompanied by air leaks, usually pneumothorax and pneumomediastinum, which now can be detected with high-intensity fiberoptic transillumination, introduced in the 1970s (74,75), allowing emergency intervention. As our ability to ventilate extremely preterm infants improved and surfactant was more widely used, the incidence of pneumothorax decreased (76). However, pulmonary interstitial emphysema remains a problem and can be extremely difficult to treat. This situation seems to be where high-frequency ventilation has been most successful (compared with conventional ventilation) (77).

Continuous distending pressure. From the observations of Avery and Mead and other studies, it was well recognized that atelectasis was a major component of RDS. The group at the University of California, San Francisco, proposed that RDS be called progressive pulmonary atelectasis to describe more accurately the pathophysiology of the disorder. Not only was assisted ventilation enhanced by using positive end expiratory pressure (PEEP), but also the principle was used *de novo* early in the course of RDS by the group at the University of California, San Francisco (78). They called this continuous positive airway pressure (CPAP), although the principle is the same as PEEP. Some infants (neonates) with RDS could be

treated with CPAP alone, although many went on to need assisted ventilation with PEEP.

Early in the application of CPAP, attempts were made to apply it with either a face mask or a head hood, but it was most successful using an endotracheal tube. Soon, a group in Cleveland used a nasal device to provide CPAP (79); nasal prongs have persisted as the preferred method of application since then, although there have been variations.

When negative-pressure ventilators were used, there was also the capability to provide continuous negative pressure. Several attempts were made to provide free-standing negative-pressure devices (a body cuirass), but they have not caught on, despite that avoiding endotracheal intubation seems to be a worthy goal. The use of continuous distending pressure has been the mainstay of all subsequent ventilatory techniques, including pressure-generated, volume-generated, or high-frequency ventilation.

Assessing fetal lung maturity. Fetal assessment is generally the domain of the obstetrician, particularly the maternal-fetal specialist, although the neonatologist has an interest in how the fetus is evaluated and treated. Louis Gluck, a pioneer in neonatology, devised a method of assessing lung maturity in the fetus using the ratio of lecithin, phosphatidyl choline, to sphingomyelin (L/S) in amniotic fluid (80). This advance resulted from earlier work that demonstrated that fetal lung fluid in the airways contributed to amniotic fluid, rather than the reverse (81). It was not uncommon, before the introduction of measurements of the L/S ratio, for obstetricians to deliver infants who were only slightly preterm and went on to develop severe RDS.

An L/S ratio of $>2:1$ usually signifies mature lungs. Subsequently, measurements of phosphatidyl glycerol in amniotic fluid were found to be even more predictive of RDS than the L/S ratio. Infants of diabetic mothers had a delay in lung maturation, which may result from fetal hypersecretion of insulin, blocking the enzyme inductive capability of cortisol in the lung. This may be overcome by careful glucose control (82,83).

Prenatal corticosteroids. The discovery and application of prenatal (antenatal) corticosteroids was concurrent with assessment of fetal lung maturity. This started in 1972 with the publication of the use of betamethasone to prevent or minimize the severity of RDS (84). Possibly because it was published in a pediatric journal but also because a subsequent collaborative study published in an obstetric journal provided a less conclusive response (85), it was several more years before the body of evidence convinced obstetricians to sign on to this remarkably beneficial adjunct in the care of the preterm infant. These data were collected in a consensus conference, published in 1994 (86,87). It was also documented that antenatal betamethasone has a protective effect against the development of intraventricular hemorrhage (IVH) (87,88).

Exogenous surfactant. After the Avery-Mead discovery of the link between surfactant lack and development of HMD (RDS) [which followed the work of Pattle (89) and Clements (90)], attempts were made to provide the major component of surfactant, dipalmitoyl phosphatidyl choline, *via* the endotracheal tube, but these proved disappointing. It was not until

1980 that Fujiwara reported success in human newborns using exogenous liquid surfactant derived from minced calf lung (91). At that time, others were working on surfactant extracts derived from human amniotic fluid or a synthetic product (92,93); there was also a powdered form of surfactant, with the acronym ALEC, for acute lung expansion compound (94).

Over the next few years, many nurseries participated in randomized, controlled, clinical trials of different products. In the United States, the two major competitors were Exosurf (a synthetic product produced by Burroughs-Wellcome) and Survanta (derived from calf lung and produced by Ross Laboratories). Although Exosurf received Food and Drug Administration approval first in 1990, Survanta was close behind and rapidly gained greater acceptance because of more rapid improvement. In Europe and Scandinavia, a porcine-derived surfactant, Curosurf, also rapidly gained ascendancy because of its rapid onset of improvement and demonstrable decrease in pulmonary mortality and morbidity (95).

There are several other competing products, which claim greater efficacy, but the success of all of these animal-derived products seems to be related to the presence of surfactant proteins (96). The impact of exogenous surfactant on neonatal survival has been enormous (97).

Cardiopulmonary monitors. Until the 1960s, the bedside nurse was responsible for taking vital signs at intervals dictated by the severity of illness of the infant. However, when it was recognized that prolonged and frequent apneic episodes might result in long-term consequences, apnea monitors were introduced (98,99). The prototypes were impedance monitors that picked up electrical signals across the chest, but pneumatic mattresses that picked up breathing movements enjoyed brief popularity. These monitors were set to alarm at 15 to 20 s of apnea. Continuous heart rate monitors also became available with a needle pointing to a number. Subsequently, cardiopulmonary monitors with a waveform displayed on a screen became standard equipment in intensive care, or special care, nurseries, as an extension of the nurse. Blood pressure monitoring was added later.

Oxygen saturation monitors. Intermittent oxygen tension measurements using microsamples of blood gave way to transcutaneous oxygen monitoring in the mid-1970s (100), a completely different view of neonatal oxygenation that provided a continuous recording. However, measurement of transcutaneous oxygen requires a heated electrode, which needs to be moved frequently to avoid skin injury, especially in the very preterm infant.

In the 1980s, pulse oximetry was introduced to neonatology (101) and rapidly gained popularity because it used a light sensor that could be wrapped around the foot or the hand to detect oxygen saturation. Because there was no heating device, the position did not need to be changed frequently. However, when the pulse was not being detected, the monitor would alarm, and this occurred frequently when the infant was moving. This problem now seems to be solved with some devices.

Apnea, sudden infant death syndrome, and methylxanthines. At the end of the 1960s, it was agreed that if attacks of apnea were frequent and prolonged, then hypoxic brain damage was likely to follow. In the early 1970s, Kuzemko won-

dered whether aminophylline might ameliorate this problem, because it was known to act on the respiratory center (102). Subsequently, other studies showed the value of aminophylline, as well as noting the interconversion of theophylline with caffeine. Caffeine then was used to treat apnea (103), and because it can be given once a day, it has gained greater acceptance.

Also in the early 1970s, the hypothesis was generated that apnea was the precursor of sudden infant death syndrome (SIDS). In some centers, this created a whole new industry of home apnea monitoring, which was based on parental fear of SIDS. This was categorized a few years ago as a fraud perpetrated on the public (104). The "Back to Sleep" campaign has been much more successful in preventing SIDS (105).

CARDIOPULMONARY SUPPORT

It is not always possible to consider the lungs in isolation, and there are several other innovations that have had an impact on the outcome of neonates, both preterm and term, that are more concerned with the circulatory system but inevitably have an impact on the pulmonary system.

Patent ductus arteriosus management. With improvements in management of RDS, many preterm infants had rapid changes in the dynamics of pulmonary blood flow, which resulted in left-to-right shunting through a patent ductus arteriosus (PDA). Most of these infants were considered too small or unstable to attempt surgical ligation of the PDA. Although this attitude has changed in recent years (with surgical ligation now being done in the corners of many NICUs), the discovery that the PDA could be closed pharmacologically with indomethacin (106,107) had a major impact on the practice of neonatology.

In some circumstances, the opposite strategy is used. Prostaglandin E has been used since 1975 to maintain the patency of the ductus arteriosus in cases of cyanotic congenital heart disease (108).

Blood pressure support. Methods of measuring systemic blood pressure in the neonate were crude until the 1970s, when umbilical arterial catheters were frequently inserted. This gave direct access to arterial blood pressure, and the normal range of blood pressure could be determined (109). Subsequently, non-invasive methods became available, which provided measurements comparable to those obtained directly. With these devices, combined with clinical evaluation of peripheral blood flow, much greater attention was given to maintenance of both adequate circulatory blood volume and blood pressure. The use of colloid and crystalloid increased markedly (110), as did the use of pressor agents, such as dopamine and dobutamine (111).

Persistent pulmonary hypertension management. With the advances in measurement of systemic blood pressure came a more sophisticated understanding of pulmonary blood pressure. Under certain circumstances, most notably with asphyxia and/or meconium aspiration syndrome, the syndrome called "persistent fetal circulation" was described (112), with persistence of right-to-left shunting at the ductus arteriosus and foramen ovale seen *in utero*. This was really a misnomer and should have been called "persistent transitional circulation,"

because the placenta was no longer in the circuit. The problem is encountered most frequently in term or postterm infants. This now is usually described as persistent pulmonary hypertension of the newborn (PPHN). There were two approaches adopted to try to correct this: either increase systemic blood pressure or decrease pulmonary blood pressure. For many years, tolazoline (Priscoline) was used to decrease pulmonary blood pressure, sometimes with dramatic success (113), but this agent had a tendency to cause a decrease in systemic blood pressure at the same time. To counter this, pressors were used. It was also noted that the condition tended to worsen with agitation or crying, so sedative/analgesia drugs were introduced and even paralysis. Thus began the era of polypharmacy for this condition.

At least two other adjuncts to therapy that have had variable acceptance were described. First, it was noted that hyperventilation seemed to produce improvement, and it was not clear for a while whether this was because of decreased CO₂ or increased pH. Subsequently, it was shown convincingly that increased pH (alkalemia) was the important component (114). Second, an agent used in obstetrics for muscle relaxation was used in the neonate. This is magnesium sulfate, which seems to have a selective effect on the pulmonary arterioles (115).

Despite any or all of these interventions, the infant went on to die in many situations. This was the result of peripheral extension of the arterial/arteriolar muscle into the capillaries (116). The most likely stimulus seemed to be chronic intrauterine hypoxemia.

Two other modes of therapy had a significant impact on the management of PPHN: 1) inhaled nitric oxide (iNO) and 2) extracorporeal membrane oxygenation (ECMO). One of the more intriguing discoveries in recent years was that iNO, acting as a selective pulmonary vasodilator, could produce marked benefit in neonates with PPHN (117,118). The early reports used considerably higher concentrations than those generally used today. The ability to deliver a therapeutic agent *via* inhalation directly to the site of the problem meant that undesirable side effects are less likely. Earlier intervention with iNO has contributed to a decrease in the number of infants who require ECMO.

When all else fails in the management of PPHN, there is always the possibility of achieving success with ECMO. This technique involves cannulation of major blood vessels, usually the carotid artery and jugular vein, and requires very careful evaluation of coagulation status. The underlying lung pathology may resolve while the pulmonary circulation is largely bypassed.

When first introduced, the studies of ECMO generated a good deal of controversy because of the statistical methods used at the University of Michigan (119) and a somewhat different but equally contentious method at Children's Hospital, Boston (120). Because of the controversy engendered, it was possible for researchers in the United Kingdom to maintain equipoise and undertake a randomized, controlled trial that confirmed the value of ECMO (121). Most centers do not undertake this form of treatment in infants who weigh <2 kg, and it is recommended that it be limited to centers that perform the procedure frequently to maintain the skills required.

Echocardiography. While considerable advances were attributed to the introduction of cardiac catheterization in the mid-20th century, the ability to detect structural abnormalities with the use of cardiac ultrasound, echocardiography, revolutionized pediatric and neonatal cardiology (122). Using Doppler techniques, the direction of blood flow could be detected. This made the detection of PDA and intracardiac shunting secondary to PPHN relatively simple.

Other advances in neonatal echocardiography are beyond the scope of this article. However, it should be mentioned that fetal echocardiography has assumed increasing importance in the past decade, allowing early diagnosis of congenital heart disease to be made and delivery at a cardiac center to be facilitated.

NEONATAL INFECTION

The start of the antibiotic era coincided with the beginning of modern neonatology. Before the introduction of penicillin, the most important organisms causing neonatal sepsis and meningitis were *Streptococcus pyogenes* (group A *Streptococcus*), *Staphylococcus aureus*, and *Escherichia coli*. The *Staphylococcus* rapidly developed resistance to penicillin and created an extremely problematic situation in most hospital nurseries. The “cloud” infant was described (123), cultures from many sites were sent, and cohort nurseries were established (124). Hexachlorophene was widely used to suppress the organism but proved to have its own hazard in premature infants, causing cystic lesions of the brain (125). When methicillin was discovered, which was effective in treating *S. aureus*, there was a great sense of relief.

The difficulty of making a definitive diagnosis of neonatal sepsis or meningitis early in its course has been recognized for decades. This limits our ability to restrict the use of antibiotics to neonates with known infection. In the 1970s, more attention was paid to interpretation of the white blood cell count and differential, as well as acute-phase proteins (126). C-reactive protein was shown in Sweden to be helpful in diagnosis as long ago as 1974 (127) but was not widely embraced in the United States. The immature to total neutrophil ratio also proved to be a useful adjunct (128,129). Until the present time, no single test has proved reliable in making an early diagnosis of sepsis, although this may be about to change if the PCR technique is used to identify bacteria (130).

In the early 1970s, *S. agalactiae* (group B *Streptococcus*) became a serious concern across the country, although isolated reports had been published earlier (131). “Early” and “late” forms of the disease were described (132). Only recently has obstetric practice changed to minimize the effect of this organism (133). However, as one bacterial organism declines, there is always another to take its place. *E. coli* has remained a fairly constant threat, and several multicenter trials were organized to evaluate the management of Gram-negative bacillary neonatal meningitis (134). Antibiotic-resistant bacteria remain a continuing concern in all nurseries. In the very low birth weight (VLBW) infant, coagulase-negative staphylococci play an important role (135) and have limited sensitivity—most are still sensitive to vancomycin—but fungal organisms, such as *Can-*

didia albicans and *Malassezia furfur*, may be very difficult to eradicate (136).

Intrauterine infection with nonbacterial organisms was well described in the 1960s, when the expanded congenital rubella syndrome was described (137) and investigation with TORCH titers became common. This acronym stood for toxoplasmosis, other, rubella, cytomegalovirus, and herpes simplex; chief among “other” was congenital syphilis (138,139). Later, we were introduced to parvovirus B₁₉, which can cause profound anemia and hydrops of the fetus (140), and on a global basis, perinatal transmission of HIV-1 has had a devastating effect on millions of infants who became HIV positive or acquired AIDS. Although perinatal transmission may now be prevented in many cases, availability of appropriate drug therapy remains a problem (141).

OTHER IMPORTANT PROBLEMS OF PREMATURITY

With advancing knowledge, the premature infant was no longer labeled a weakling but was evaluated carefully and found to have a variety of definable problems, many of which are now treatable. Several important problems deserve further comment.

Necrotizing enterocolitis. Necrotizing enterocolitis continues to be a major complication that develops in the most immature infants. Mortality was extremely high until the early 1970s, at which time a group of physicians at the University of Washington noted that early recognition and aggressive medical and surgical management could significantly reduce mortality (142). In addition, staging of the disease process has allowed better evaluation of the various approaches to diagnosis and care. Pediatric surgeons are currently conducting a randomized, controlled trial of immediate exploratory laparotomy *versus* simple drainage followed by later exploration. Despite a better understanding of the disorder and that feeding with breast milk provides some protection, necrotizing enterocolitis still affects 7–10% of infants with birth weight <1500 g and causes increased morbidity and prolonged hospitalization (143).

IVH/periventricular hemorrhage. Brain imaging was introduced into neonatology in the mid-1970s (144). This was initially with computed tomography, which revolutionized our ability to determine whether intracranial hemorrhage had occurred. In 1979, the first reports of ultrasound imaging of the brain were published (145). This was even more exciting, because it could be done at the bedside, whereas computed tomography scanning required moving the infant to the machine (still not an easy task when an infant is on assisted ventilation). Particularly with head ultrasound, it was possible to confirm rapidly (or refute) the clinical suspicion of IVH. Too often, clinical impressions proved to be incorrect, and many sick infants with falling hematocrits were found not to have intracranial hemorrhage (146).

Cranial ultrasound allowed better understanding of the pathophysiology of IVH/periventricular hemorrhage (PVH), but it remains a comparatively common problem in the extremely preterm infant, especially before 29 wk gestation. The

incidence of grade 3 (hemorrhage dilating the ventricles) and grade 4 (extension of hemorrhage into the brain parenchyma) IVH/PVH has decreased significantly in the past 20 y (147), particularly with the increased use of prenatal corticosteroids (87,88), improved recognition and treatment of chorioamnionitis, improved obstetric management, and postnatal use of indomethacin (148). Nevertheless, up to 15% of VLBW infants (<1500 g) are still affected by IVH/PVH, which is likely to have long-term adverse consequences on neurodevelopmental outcome (149,150).

Whereas sequential head ultrasound scanning is frequently used early in the neonatal course, magnetic resonance imaging, which was introduced approximately a decade afterward, is the preferred technique. Magnetic resonance imaging provides greater definition and clearly delineates white and grey matter. Adding spectroscopy to the imaging yields more information about function and structure (151).

ROP. Formerly called retrolental fibroplasia because in its most severe form the retina may be scarred or even become detached, ROP causes considerable heartache. The role of the misuse of oxygen in its cause has been well documented by William Silverman (18), but this is a complex disorder that is still being elucidated (152). The disorder cannot be evaluated until the blood vessels of the retina are of a certain maturity; examinations usually start at 6 wk after birth, so this is usually the last of the problems of prematurity to declare itself. In the sickest of preterm infants (<29 wk gestation), it hangs over parents like the sword of Damocles. It is usually not possible to provide reassurance that the eyes have been spared until close-to-term gestation.

At one time, severe stages of ROP inevitably resulted in blindness, but in the past 15 y, there has been considerably more optimism. In 1988, the first ray of hope was provided by a preliminary report of improved outcome in severe ROP with the use of cryotherapy (153). Subsequently, the more usual approach is to ablate the proliferating blood vessels with laser therapy, with or without cryotherapy. Although this does not guarantee normal vision, it is more likely that there will be a successful outcome.

NEONATAL SURVIVAL

Although neonatal mortality is defined as deaths that occur before 28 d after birth, many authors in recent years have considered that all deaths before discharge from the nursery should be considered in that statistic. Thus, survival to discharge may be a more appropriate way of looking at things. Parents, before delivery at an early gestational age, want to know two things: 1) what are the chances that the infant will survive; and 2) if the infant survives, what are the chances of neurodevelopmental disability?

As recently as the mid-1960s, extremely low birth weight (ELBW; <1000 g) infants had a survival rate of ~5% (*i.e.* the mortality rate was 95%) (154); by 2000, the survival rate in neonates with birth weight 901–1000 g was 95%. In 1960, infants who were born at <28 wk gestation were considered “preivable.” Today, >50% of infants who are born at 24 wk gestation survive (149).

The gestational age at which 50% of neonates survived decreased from 29 wk in 1960 to 24 wk by the early 1990s. Although the long-term outcome for VLBW (<1500 g) survivors was poor in the 1960s (155), infants with birth weights of 1000–1500 g now do well. However, the number of infants with disabilities has stayed approximately the same because of increased survival at lower gestational ages. In survivors who are born at 23–24 wk gestation, major disabilities occur in 20% and mild to moderate disabilities occur in an additional 20–30% (150). This means that 50% of such infants may be normal. Unfortunately, it is difficult to predict accurately into which half an infant will fall.

Neonatal survival and/or mortality is strongly linked to the number of premature or LBW infants born. Intensive efforts to decrease the incidence of prematurity using a number of different strategies have had very little impact on the problem. In the United States, the incidence of prematurity has increased in recent years. This is largely due to an increase in the number of multiple births (twins, triplets, and higher), which are more likely to result in a preterm delivery. Approximately 25 y ago, multiple births accounted for 1.8% of all pregnancies, whereas currently, the proportion is ~2.5%.

This increase in multiple births is the result of advances in assisted reproduction techniques such as pharmacologic induction of ovulation, standard *in vitro* fertilization, and intracytoplasmic sperm injection, which now are commonplace. However, even with certain safeguards (*e.g.* implanting only two embryos), the risk for multiple births is high (156). Not only that, a recent study from Australia (157) showed that there may be an increased risk for birth defects. Assisted reproductive techniques accounted for >40% of multiple pregnancies beyond simple twinning and for many more LBW and VLBW infants (158).

REGIONALIZATION/DEREGIONALIZATION

In the late 1960s and early 1970s, many areas of medicine were the beneficiaries of the Regional Medical Programs initiative started in 1965. In some areas, neonatal care benefited from this initiative—although heart disease, cancer, and stroke were targeted—and the success of these programs resulted in wider dissemination of the concept. In addition, comparative data indicated that mortality and morbidity were higher in infants who were transferred to centers after birth in comparison with those who were born at the center (159). When mothers were transferred to the center to deliver, the data showed that such maternal–fetal transfers had mortality and morbidity that was similar to those who originally planned to deliver at the center (160).

One of the prime movers in this movement was Joseph Butterfield, along with Jerold Lucey and others. In October 1970, an *ad hoc* committee met in Denver. The group composed a policy statement on regionalization and/or centralization of perinatal care that was endorsed by the American Medical Association House of Delegates in August 1971 (161).

When NICUs were first introduced, only the fittest infants who were born in community hospitals were able to survive the trip to the regional center. However, this era was followed by

concentration on improving the transport of neonates (162). Such a system was necessary when there were limited resources of equipment and personnel. However, as more and more people went into this new specialty of neonatology, any hospital with aspirations to be a full-service provider decided that it would build a NICU. This resulted in a very competitive climate in some areas, where the number of NICU beds exceeded the demand. There was some natural attrition for a while, but when survival of small infants improved, it was sometimes difficult for the centers (usually academic centers) to be able to accommodate all of the infants who were eligible for transfer. This further stimulated development of NICUs in nonacademic centers.

In the early days of neonatology, the expertise was largely confined to academic centers, where research was conducted. By the late 1980s, many neonatologists preferred the freedom of providing only clinical care and did not want to worry about competing for grant support to conduct research. Consequently, many of them went private.

A certain amount of deregionalization has occurred, which was possible as a result of the expanding numbers of physicians, nurses, and respiratory therapists. In addition, in many areas, having an infant many miles away from where the parents live created an unnecessary burden, especially when appropriate care could be provided closer to home. This resulted in attempts to back-transfer infants when the acute phase of their illness resolved. This is not always what parents want but has become an option for neonates who require an extended hospital stay, usually the very preterm infant.

The concept of concentrating the sickest patients in regional centers persists, despite the establishment of nurseries that are capable of providing a high level of care in community hospitals. For instance, in California, the state designates four levels of care for nurseries. Level 3 is a community NICU, which may be capable of providing assisted ventilation but would not normally perform neonatal surgery or have a large number of consultative services available. Level 4 is a regional NICU, to which community NICUs relate. These NICUs provide the complete range of consultative services—pediatric surgery, cardiology, neurology, ophthalmology, genetics, endocrinology, etc.—and are most commonly affiliated with an academic center.

Although neonatal transfer remains an option and is usually accomplished safely with the use of specialized teams that are trained for this purpose, it is still considered desirable for most extremely preterm fetuses, particularly <30 wk gestation, to be transported *in utero* for delivery at the regional center (163). With increased detection of congenital malformations using prenatal ultrasound, it is also usually the case that such infants, who are likely to require surgery, will be delivered at a regional center. In this way, a multidisciplinary approach can be coordinated more easily. All of this has improved the care provided to mothers and infants in a region.

Home birth movement. The home birth movement could be considered as an extreme extension of deregionalization. In the mid-1970s, there was an upsurge in the belief that the most natural place to deliver was at home. This movement was led by lay midwives, rather than nurse midwives, many of whom

were unwilling to acknowledge the risks inherent in delivering infants at home. To counter this movement, a number of hospitals introduced “alternative birth centers” with a more home-like environment for low-risk patients (164). Recently, the pendulum seems to have swung back again, with the realization that emergencies cannot be dealt with adequately at home.

Perinatal outreach education. To make a regional program work effectively, there needs to be a close collaboration among maternal-fetal medicine physicians, neonatologists, and perinatal nurses. Community obstetricians, pediatricians, and family practitioners need to learn what they can do under certain circumstances to make sure that mothers and infants receive the best care possible. In addition to stabilization techniques, they need to know what is available at the regional center. The most effective way to do this is to interact personally with referring physicians. In most perinatal regions, this is accomplished through Outreach Education (165). This kind of interdisciplinary collaboration is one of the major changes that has occurred in the past 40 y.

PARENT-INFANT INTERACTION

Although it may not seem to be an obvious advance in neonatology, it is important to understand the change that has occurred in the attitudes of physicians and nurses to the role of parents in the care of their infants. When I was a pediatric resident, I was barely allowed to enter the premature nursery and parents were allowed to view their infants only through a glass partition [see also (6,18)]. There was great emphasis placed on the susceptibility to infection of the premature infant.

All of this changed at the end of the 1960s, with an initial study by Barnett *et al.* (166) at Stanford, but was subsequently in response to the work of Marshall Klaus and John Kennell, who promoted the idea of “bonding.” Although this was initially concentrated on maternal-infant interaction (167), it rapidly expanded to include fathers (168). T. Berry Brazelton published his Behavioral Assessment Scale (169) and drew our attention to differences in interactions of infants with fathers. With greater involvement in the nursery, parents gradually assumed more responsibility for decisions concerning their infants. The old paternalistic attitudes of physicians were replaced by a team approach that included the parents. Although it is not always possible, because delivery may occur too rapidly, prenatal consultation with both parents by a neonatologist now is the norm when a mother is in preterm labor at 23–25 wk gestation to discuss possible options regarding resuscitative efforts and subsequent management (170).

Not only were parents encouraged to come to the bedside or incubator-side and touch the infant and hold the infant, if he or she was not attached to too much equipment, but also mothers were encouraged to contribute to the care of their infants by providing expressed breast milk (171). This aspect of care allowed both parents to feel more engaged with their infants as fathers are frequently the transporters of frozen breast milk for storage. In some developing countries, the concept of “kangaroo” care was introduced (172) and such skin-to-skin contact

now is frequently encouraged in nurseries in the United States (173).

NEONATAL METABOLIC SCREENING

One well-established procedure at present, which “always seems to have been around” but was introduced <50 y ago, is screening for metabolic disease using blood spots on filter paper. The first test, introduced in Massachusetts, was a test for phenylketonuria, called the Guthrie test (174). This was initially proposed as a urine test but then applied to blood spots and was based on a bacterial inhibition assay, introduced in 1961 because increased levels of phenylalanine enhance bacterial growth (175). States rapidly introduced legislation to support the screening of this disorder in all infants at the time of discharge from the hospital (in term infants).

The PKU test, as it was called for many years, had several other inborn errors of metabolism added to the screening over the next decade, such as homocystinuria, maple-syrup urine disease, and galactosemia. Screening for congenital hypothyroidism was introduced in the early 1970s (176). This was superimposed on the system already in place, at a time when some were questioning the utility of metabolic screening, because most disorders had an incidence of 1:10,000–1:125,000, or more. However, congenital hypothyroidism has an incidence of 1:3000–1:5000.

Several more tests were added to these basic screening tests in different states (*e.g.* assessment of biotinidase deficiency, testing for hemoglobinopathies, immunoreactive trypsin for cystic fibrosis) depending on the racial distribution of the population. Recently, many more (but rare) inborn errors of metabolism can be screened using blood spots and the technique of tandem mass spectrometry (177). Unfortunately, the current economic climate has limited state support for this technique in some states.

JAUNDICE

Over the past 40 y, there has been an enormous change in the cause of severe hyperbilirubinemia, manifest most commonly in the neonate as profound jaundice. Whereas 40 y ago, Rhesus incompatibility was a major problem, resulting in the need to perform large numbers of exchange transfusions to prevent the development of kernicterus, it now has been virtually eradicated (178). Consequently, many pediatric residents and some fellows in neonatology finish their training without having performed an exchange transfusion, almost incomprehensible to the older generation!

Globally, glucose-6-phosphate dehydrogenase deficiency probably contributes the largest proportion of infants with severe hyperbilirubinemia. Studies conducted over more than a decade, particularly in Greece, indicate that tin-mesoporphyrin, which is a potent inhibitor of heme oxygenase, can be used as an alternative to exchange transfusion or as prophylaxis against severe hyperbilirubinemia (179).

In the preterm infant and others, phototherapy is the mainstay of treatment. Early discharge of term infants has become the norm and makes the task of detecting and preventing severe hyperbilirubinemia more difficult (180). One adjunct that

should facilitate detection is the use of transcutaneous bilirubinometry, first introduced in Japan (181), which is a screening tool and lessens the need for blood tests. There now are published norms for age-specific levels of total serum bilirubin, hour by hour from 18 to 168 h after birth (182). In conjunction with assessment of end-tidal carbon monoxide, corrected for ambient CO, the task of early detection of the at-risk neonate is somewhat easier (183). Increased vigilance has been emphasized in recent years, because of the re-emergence of kernicterus, a disorder that should be entirely preventable (184).

Phototherapy. Phototherapy started in 1958 (185), and 10 y after its introduction, it was reintroduced in the United States for use in preterm infants by Jerold Lucey (186). There was contentious debate about its safety in the early days, but it now is an established treatment modality that helps to prevent kernicterus in preterm infants. Although overhead lights are usually used, the application of eye shades often upsets parents. Bili-blankets, using fiberoptics, now can be wrapped around the infant to avoid the need for eye protection (187); also a new phototherapy light source, using high-intensity, light-emitting diodes, has been shown to be at least as effective as conventional phototherapy (188).

CHANGES IN ROUTINE PRACTICES

Routine neonatal care has changed substantially in the past 50 y. Although well-infant nurseries are primarily the domain of the general pediatrician, they provide the basis of neonatology. Since 1983, the AAP has published jointly with the American College of Obstetricians and Gynecologists “Guidelines for Perinatal Care,” now in its fifth edition (189).

Previously, it was thought necessary to wear caps, gowns, and masks before entering any nursery. Today the emphasis is on hand washing. Other areas of care that have changed include umbilical cord care, eye prophylaxis, sleep position (105), and identification procedures. Three additions to routine care are 1) administration of Hepatitis B vaccine, 2) hearing screening (190), and 3) use of car seats (191). With regard to this last item, attitudes toward automobile safety have changed for all ages, but special considerations apply to premature infants at discharge (192).

ROLE OF WOMEN IN NEONATOLOGY

Perhaps in no other pediatric specialty has the role of women been greater than in neonatology. As already mentioned, Virginia Apgar and Mary-Ellen Avery contributed seminal works that had an enormous influence on the care of neonates. Other pioneers were Mary Crosse at the Sorrento Maternity Hospital in Birmingham, England; Beryl Corner in Bristol, England; Ethel Dunham of Yale University, New Haven, Connecticut; Lula Lubchenco in Denver, Colorado; Murdina Desmond in Houston, Texas; Joan Hodgman in Los Angeles; and Mildred Stahlman in Nashville, Tennessee.

Maria Delivoria-Papadopoulos was one of the first to investigate the use of positive-pressure ventilation in RDS, and Mildred Stahlman was using the negative-pressure ventilator at approximately the same time. The perinatal pathologists Edith Potter, in Chicago, and Jeanne-Claudie Larroche, in Paris, and

the neuropathologist Betty Banker, in Cleveland, have greatly influenced our understanding of neonatal disorders.

Claudine Amiel-Tison, in Paris, learned neonatal neurologic assessment at the feet of André Thomas and Suzanne St. Anne-Dargassies and then expanded their observations to the very preterm infant, with extended follow-up observations. Other women who have made careful follow-up of preterm infants their life's work are Cecil Mary Drillien in Edinburgh; Lula Lubchenco in Denver; Ann Stewart in London; Betty Vohr in Providence, Rhode Island; Maureen Hack in Cleveland; and Saroj Saigal in Hamilton, Ontario, at McMaster University. For many years, the name of Lily Dubowitz was synonymous with gestational age assessment, and her scoring system was more recently modified by Jean Ballard.

Bilirubin metabolism and the prevention of kernicterus have been the domain of Audrey Brown, a neonatal hematologist, and Lois Johnson, whereas the prevention of ROP (retrolental fibroplasia) has greatly benefited from the work of Kate Campbell, in Australia, in the early years (1951) [see (18)] and of Dale Phelps in more recent years. Roberta Ballard was long an advocate of antenatal steroids to prevent RDS; Billie Short was a leader in the use of ECMO; and the first reported use of computed tomography to detect IVH was by Lu-Ann Papile and co-workers.

Renate Huch, with her obstetrician husband Albert, in Germany and later in Switzerland, introduced both transcutaneous PO_2 and P_{CO_2} electrodes into perinatal medicine, especially into neonatology. The team of Victoria Smallpeice and Pamela Davies in Oxford, England, introduced early feeding of human breast milk to premature infants at a time when it was considered controversial.

Leaders (chairpersons) of the Perinatal Section of the AAP include Marilyn Escobedo and Ann Stark. Lillian Blackmon recently chaired the Committee on Fetus and Newborn of the AAP, and Sherin Devaskar recently became the Editor-in Chief of *Pediatric Research*.

NEONATOLOGY AND THE PEDIATRIC SOCIETIES

The American Pediatric Society was established in 1888, and in its centennial year, the newborn infant was one of four featured areas at the annual meeting (193). In the late 1960s and 1970s, the American Pediatric Society–Society for Pediatric Research meeting was a very exciting place to be, with many new discoveries presented. In the words of Murdina Desmond: “As the end of the baby boom (1946–64) approached, neonatology took its place as a major division of pediatrics. At pediatrics meetings, newborn research was presented to standing-room only audiences” (6).

The Perinatal Section was established within the AAP in late 1974. A list of chairpersons is provided in Table 1. The first 25 y of the Perinatal Section were summarized by L. Joseph Butterfield, an early promoter and staunch supporter of the section until his death in 1999 (194).

In 1975, both the first examination of the Sub-Board of Neonatal-Perinatal Medicine (for the chairpersons, see Table 2) and the first meeting of the Perinatal Section were held. The first chairman of the section, William H. Tooley, presided over

Table 1. *Chairs of the Perinatal Section of the AAP*

1975 - William H. Tooley, M.D.
1977 - George A. Little, M.D.
1979 - George Cassady, M.D.
1981 - George J. Peckham, M.D.
1983 - L. Joseph Butterfield, M.D.
1986 - William J. Keenan, M.D.
1988 - Marilyn B. Escobedo, M.D.
1990 - John D. Driscoll, M.D.
1992 - James A. Lemons, M.D.
1994 - David K. Stevenson, M.D.
1996 - Richard A. Molteni, M.D.
1998 - Ann R. Stark, M.D.
2000 - Gerald B. Merenstein, M.D.
2002 - Michael E. Speer, M.D.

Table 2. *Chairs of the Sub-Board of Neonatal-Perinatal Medicine (of the American Board of Pediatrics)*

1974–1975	Stanley N. Graven, M.D.
1976–1978	Thomas K. Oliver, Jr., M.D.
1979–1980	L. Stanley James, M.D.
1981–1982	James M. Sutherland, M.D.
1983–1984	Nicholas M. Nelson, M.D.
1985–1987	Michael A. Simmons, M.D.
1988–1989	M. Jeffrey Maisels, M.D.
1990–1991	Avroy A. Fanaroff, MB.B.Ch., F.R.C.P.E.
1992–1993	Roberta A. Ballard, M.D.
1994–1995	M. Douglas Jones, Jr., M.D.
1996–1997	Thomas N. Hansen, M.D.
1998–1999	Ann R. Stark, M.D.
2000–2001	David K. Stevenson, M.D.
2002–2003	Alan H. Jobe, M.D.
2004–2005	Christine A. Gleason, M.D.

Terms begin January 1 and end December 31.

the presentation of the Apgar Award to Clement A. Smith, who had recently (in 1974) relinquished the Editorship of *Pediatrics* to Jerold F. Lucey (another neonatologist, who still holds that position!). The list of recipients of the Apgar Award, presented to “an individual whose career has had a continuing influence on the well-being of newborn infants,” is provided in Table 3.

In 1993, Dr. Leonore Ballowitz from Berlin, Germany, gave the first Thomas E. Cone, Jr., M.D., Lecture on Perinatal History on “The Life of Arvo Ylppö. Other speakers and topics are provided in Table 4.

ERRORS IN NEONATOLOGY

Although it would be comforting to think that modern neonatal care evolved seamlessly in a series of logical steps, there were many missteps along the way. Many of these were outlined by Dr. William Silverman in his book *Retrolental Fibroplasia* (18). In addition, Dr. Alex Robertson recently published three papers detailing some major mistakes that have occurred in neonatology (195–197). The second and third papers are concerned with errors that occurred since 1950. A summation is provided in Table 5.

One example is the uncontrolled introduction of gastrostomy feeding for preterm infants in the early 1960s. Gastrostomy feeding was initially introduced as an adjunct to care of infants on ventilators. Unfortunately, this technique was rapidly introduced to the care of other preterm infants. It was abandoned at

Table 3. Virginia Apgar Award Recipients

1975	Clement A. Smith, M.D.	1990	Petter Karlberg, M.D.
1976	Richard L. Day, M.D.	1991	Mary Ellen Avery, M.D.
1977	Donald H. Barron, M.D.	1992	L. Joseph Butterfield, M.D.
1978	Nicholas Assali, M.D.	1993	Jerold F. Lucey, M.D.
1979	William A. Silverman, M.D.	1994	John A. Clements, M.D.
1980	Geoffrey S. Dawes, FRS, M.D.	1995	William Oh, M.D.
1981	Louis K. Diamond, M.D.	1996	Frederick C. Battaglia, M.D.
1982	Lula O. Lubchenko, M.D.	1997	Maria Delivoria-Papadopoulos, M.D.
1983	Edward Hon, M.D.	1998	Kurt Benirschke, M.D.
1984	Giacomo Meschia, M.D.	1999	Joan E. Hodgman, M.D.
1985	L. Stanley James, M.D.	2000	Robert H. Usher, M.D.
1986	Graham C. Liggins, M.B., Ch.B.	2001	Philip Sunshine, M.D.
1987	Mildred T. Stahlman, M.D.	2002	Avroy A. Fanaroff, M.B., Ch.B.
1988	Murdina M. Desmond, M.D.	2003	Eduardo H. Bancalari, M.D.
1989	William H. Tooley, M.D.		

Table 4. Thomas E. Cone, Jr., M.D. Lectures on Perinatal History

Year	Speaker	Topic
1993	Leonore Ballowitz, M.D.	"The Life of Arvo Ylppö"
1994	Joan Beck (journalist)	"I Remember Virginia Apgar"
1995	William A. Silverman, M.D.	"Proto-Neonatology: The Children's Bureau and Ethel Dunham"
1996	Marie McCormick, M.D., M.P.H. George Ryan, M.D.	"The Transition of Regional Perinatal Care in a Changing Economic Landscape" "Sprague Gardiner, M.D.: A Pioneer in the Regionalization of Perinatal Care"
1997	Peter M. Dunn, M.D.	"Neonatology in the U.K.: From V. Mary Crosse Forward"
1998	Philip Sunshine, M.D.	"Pediatric Surgery from the Viewpoint of a Neonatologist"
1999	Jeffrey P. Baker, M.D.	"The Incubator - the Icon of the NICU"
2000	Paul Toubas, M.D.	"The Life and Work of Dr. Pierre Budin"
2001	William A. Silverman, M.D.	"From Oxygen to Retrolental Fibroplasia (RLF) to the Present Retinopathy of Prematurity (ROP)"
2002	Lawrence M. Gartner, M.D.	"Tetanus of the Newborn: What the Chinese Knew 2000 Years Ago"
2003	Abraham M. Rudolph, M.D.	"Surgery for Congenital Heart Disease"

Table 5. Errors in neonatology

Event	Result	Years
The "hands-off" years (1920–1950)		
Lowered thermal environment	Increased mortality	1900–1964
Supplemental oxygen	ROP (RLF)	1941–1954
Late feeding	Hypoglycemia/neurologic deficits	1945–1970
The "heroic" years (1950–1970)		
Sulfisoxazole prophylaxis	Kernicterus	1953–1956
Chloramphenicol overdose	"Gray-baby" syndrome	1956–1960
Hexachlorophene bathing	Brain lesions	1952–1971
Feeding gastrostomy in VLBW	Increased mortality	1963–1969
Equipment cleaning	Jaundice	1972–1975
The "experienced" years (1970–2000)		
Neo-Mul-Soy formula	Metabolic alkalosis	1978–1979
Premature infant formulas	Lactobezoars	1977–1980
Erythromycin	Pyloric stenosis	1976–1999
Benzyl alcohol	"Gasping" syndrome	?–1982
Intravenous vitamin E	Multiorgan damage	1983–1984

Modified from The "hands-off" years, 1920 to 1950 by AF Roberson with permission from The Journal of Perinatology, © 2003 Macmillan Publishers Ltd.

the end of the 1960s, when a randomized, controlled trial showed no benefit of gastrostomy; in fact, both mortality and morbidity were increased in the gastrostomy group (198).

WHAT DOES THE FUTURE HOLD?

In some ways, the future is now. Certain activities are occurring in some centers that are likely to be reproduced and

become standard operating procedure in the future. The difficulty is to know which of these activities will persist. Ten years ago, I would have strongly predicted that liquid ventilation with perfluorocarbons (199) would be a major therapeutic technique in most university or research centers at the present time. However, it has not emerged as the force that many would have predicted.

Simulation techniques. My colleague Lou Halamek has developed a simulated delivery room in which realistic maternal and infant mannequins can have their vital signs manipulated so that students, residents, nurses, etc. can practice resuscitation and other emergency responses while being videotaped. Such simulation activity allows people to become proficient and respond appropriately, before being subjected to a real, live, situation. There is also simulation for responding to emergencies in an infant who is on ECMO (<http://cape.lpc.org>). Other centers are likely to adopt these approaches, and in the future, they may evolve into the use of virtual reality techniques.

Multidisciplinary/multicenter studies. In recent years, the National Institute on Child Health and Human Development network and the Vermont-Oxford Network (VON) have attempted to answer questions about clinical medicine by developing research protocols that can be used in a large number of centers to answer those questions in a much shorter time frame than would have been possible several years ago.

A number of quality improvement initiatives have also been started. A select group of ~10 centers in the VON engaged in quality improvement cycles focusing on specific goals during

the 1990s (200). By gathering data from a large number of centers, benchmark centers, with the lowest rates, could be identified and used to evaluate how improvements could be made in other centers. The VON database, now used by >400 NICUs around the world, is limited to neonates with birth weights <1500 g (VLBW).

A more recent VON quality improvement initiative was titled NIC/Q 2000 and involved a larger number of centers (201). In California, there was the development of the California Perinatal Quality Care Collaborative, which includes larger infants who are sick, as well as the VLBW infants. Individual centers can evaluate themselves against the total cohort to understand where possible improvements might occur. This allows interventions to be introduced and cycles of change to occur (202).

It seems likely that these initiatives will expand even further in the future and will allow the best practices to be identified and endorsed. I believe that such evidence-based medicine will be very important in the future (203).

Gene therapy. I would have predicted a decade ago that gene therapy would be a daily occurrence in the year 2004, but there have been a number of setbacks in translating potential into practice. Nevertheless, it seems likely that the difficulties associated with this technique will be overcome in the future. After identifying a single genetic defect as the cause of a problem in a neonate, it will be possible to replace the defective gene.

Biologic reporters. Light-emitting enzymes, luciferases, can label genes and cells. These internal light sources can be detected externally and become biologic indicators or reporters. This bioluminescent imaging has been used with target and therapeutic genes in living laboratory animals to analyze gene delivery and to monitor gene expression and immune therapies (204,205). Extension of these techniques to human newborn infants seems likely.

Artificial placenta. One of the topics that has been mentioned for as long as I have been in neonatology is the development of an artificial placenta. This futuristic idea remains just that, and I doubt that hooking up an infant to an artificial placenta will occur any time soon.

The changing role of pediatricians. With every passing year, the pediatric residency program seems to add another requirement that residents must satisfy to be a certified pediatrician. Over the past decade or more, the amount of time that residents spend in critical care units has been cut back substantially. Consequently, today's pediatric residents are not as well prepared to deal with unusual findings or neonatal emergencies. This has resulted in increasing reliance on neonatologists to provide consultations in well-infant nurseries, with further erosion of the general pediatrician's skills with the neonate. This trend is likely to continue and may result in the expansion of the neonatal nurse practitioner workforce (206).

Rapid identification of infectious disease. Presently, a number of viruses and bacteria can be detected using PCR techniques to make a rapid diagnosis (130). In the future, it seems likely that specimens will be screened with PCR to detect a battery of pathogenic organisms, and more judicious use of antibiotics will be needed to prevent the emergence of resistant organisms.

New vaccines. Considerable progress has been made in developing GBS vaccines to individual subtypes (207). In the future, a polyvalent vaccine should be available as will a vaccine against HIV.

Blood substitutes. Although each transfusion of blood in the neonate is comparatively small, NICUs are among the heaviest users of blood banks. Despite all of the safeguards to keep the blood supply free from contamination, it still seems worthwhile to seek blood substitutes.

Technological advances. It is already possible to gain access to fetal cells and to grow them selectively. This offers therapeutic potential (208), and such tissue engineering has already occurred (209).

There has been a recent surge of interest in harvesting blood from the placenta to provide autologous blood transfusion in preterm infants (210), which minimizes demands for donor blood and its attendant risks.

Newer imaging techniques have been described in animal or experimental models (152). These are likely to reach the bedside soon along with skin surface electrodes that can measure glucose, electrolytes, and other biochemical determinations.

Better understanding. There are many areas that still require elucidation and may yield answers with practical applications. Examples are 1) a better understanding of thrombophilia, which on the maternal side may be implicated in preeclampsia and IUGR and in the neonate may influence thrombotic complications; 2) a better understanding of organ damage and repair; and 3) an improved recognition and treatment of genetic disorders. Perhaps most important of all would be a better understanding of how to prevent prematurity.

CONCLUSION

In the past 50 y, there has been remarkable change in the care of the neonate. Particularly, the outlook for infants with birth weights of ~1 kg has changed from 95% mortality to 95% survival. This report provides an overview of the development of the most important principles and concepts that form the basis of neonatology today. As neonatologists, we owe an enormous debt to our predecessors, but we are still faced with many challenges for the future.

Acknowledgments. I thank Philip Sunshine, M.D., for encouragement, recollections, and suggestions.

REFERENCES

Readers may wish to consult a series of "Historical Perspectives" that have appeared monthly since October 2002 in the journal "NeoReviews," available at www.NeoReviews.org, published by the AAP. In addition, the development of neonatal intensive care in the United Kingdom has been chronicled in "Origins of Neonatal Intensive Care in the UK." In: Christie DA, Tansey EM (eds) Wellcome Witnesses to Twentieth Century Medicine, Vol 9 Wellcome Trust, London, 2001, pp 1-75.

1. Ballantyne JW 1923 The new midwifery. *BMJ* 1:617-621
2. Grulee CG 1939 The newborn. President's address to the American Pediatric Society. *Am J Dis Child* 58:1-7
3. Apgar V 1953 A proposal for a new method of evaluation of the newborn infant. *Curr Res Anesth Analg* 32:260-267

4. Cone TE Jr 1985 History of the Care and Feeding of the Premature Infant. Little Brown Co, Boston
5. Cone TE Jr 1983 Perspectives in Neonatology. In: Smith GF, Vidyasagar D (eds) Historical Review and Recent Advances in Neonatal and Perinatal Medicine, Vol 1. Mead Johnson Nutritional Division, pp 9–33
6. Desmond MM 1998 Newborn Medicine and Society. European Background and American Practice (1750–1975). Eakin Press, Austin
7. Hess JH, Lundeen EC 1941 The Premature Infant. Its Medical and Nursing Care. J.B. Lippincott, Philadelphia
8. Parmalee AH Sr 1952 Management of the Newborn. Year Book Publishers, Chicago
9. Dunham EC 1948 Premature Infants. A Manual for Physicians. Children's Bureau Publication No. 325, U.S. Government Printing Office, Washington, DC
10. Crosse VM 1945 The Premature Baby. Churchill Livingstone, London
11. Barcroft J 1946 Researches on Prenatal Life, Vol 1. Blackwell Scientific Publications, Oxford
12. Smith CA 1947 The Physiology of the Newborn Infant. C.C. Thomas, Springfield
13. Dawes GS 1968 Foetal and Neonatal Physiology. Year Book Medical Publishers, Chicago
14. Schaffer AJ 1960 Diseases of the Newborn. WB Saunders, Philadelphia
15. O'Brien D, Ibbot FA 1964 Laboratory Manual of Pediatrics. Micro and Ultramicro-biochemical Techniques, 3rd Ed. Harper and Ross,
16. Nelson NM 1983 Perinatal medicine. In: Smith GF, Vidyasagar D (eds) Historical Review and Recent Advances in Neonatal and Perinatal Medicine, Vol 1. Mead Johnson Nutritional Division, pp 3–8
17. Silverman WA 1979 Incubator-baby side shows (Dr. Martin A. Couney). Pediatrics 64:127–141
18. Silverman WA 1980 Retrolental Fibroplasia. A Modern Parable. Grune and Stratton, New York
19. Baker JP 2000 The incubator and the medical discovery of the premature infant. J Perinatol 20:321–328
20. Cone TE Jr 1981 The first published report of an incubator for use in the care of the premature infant (1857). Am J Dis Child 135:658–660
21. Silverman WA, Fertig JW, Berger AP 1958 The influence of the thermal environment upon the survival of newly born premature infants. Pediatrics 22:876–886
22. Sinclair JC 1970 Heat production and thermoregulation in the small-for date infant. Pediatr Clin North Am 17:147–158
23. Hull D 1966 The structure and function of brown adipose tissue. Br Med Bull 22:92–96
24. 1970 Symposium on "the small-for-date infant." Pediatr Clin North Am 17:1–202
25. Hey EL 1975 Thermal neutrality. Br Med Bull 31:69–74
26. Dafoe AR 1940 The survival of the Dionne quintuplets. Am J Obstet Gynecol 39:159–164
27. Schreiner RL, Brady MS, Erust JA, Lemons JA 1982 Lack of lactofozars in infants given predominantly whey protein formulas. Am J Dis Child 136:437–439
28. Zimmerman DR, Guttman N 2001 "Breast is best": knowledge among low-income mothers is not enough. J Hum Lact 17:14–19
29. Lucas A, Hudson GJ 1984 Preterm milk as a source of protein for low birthweight infants. Arch Dis Child 59:831–836
30. Toubas PL 2001 Unanticipated consequences of early advances in newborn medicine. Perinatal Section News 27:1–4
31. Royce S, Tepper C, Watson W, Day R 1951 Indwelling polyethylene nasogastric tube for feeding premature infants. Pediatrics 8:79–81
32. Smallpeice V, Davies PA 1964 Immediate feeding of premature infants with undiluted breast-milk. Lancet 13:1349–1352
33. Cornblath M, Wybregt SH, Baens GS, Klein R 1964 Symptomatic neonatal hypoglycemia. Studies of carbohydrate metabolism in the newborn infant, VIII. Pediatrics 33:388–402
34. Dudrick SJ, Wilmore DW, Vars HM, Rhoads JE 1968 Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery 64:134–142
35. Dudrick SJ, Rhoads JE 1972 Total intravenous feeding. Sci Am 226:73–80
36. Driscoll JM Jr, Heird WC, Schullinger JN, Gongaware RD, Winters RW 1972 Total intravenous alimentation in low-birth-weight infants: a preliminary report. J Pediatr 81:145–153
37. Shaw JCL 1973 Parenteral nutrition in the management of sick low birthweight infants. Pediatr Clin North Am 20:333–358
38. Heird WC, Kashyap S, Gomez MR 1991 Parenteral alimentation of the neonate. Semin Perinatol 15:493–502
39. Kerner JA Jr, Sunshine P 1979 Parenteral alimentation. Semin Perinatol 3:417–434
40. Denne SC 2001 Protein and energy requirements in preterm infants. Semin Neonatol 6:377–382
41. Putet G 2000 Lipid metabolism of the micropremie. Clin Perinatol 27:57–69
42. McClure RJ 2001 Trophic feeding of the preterm infant. Acta Paediatr Suppl 90:19–21
43. Lubchenco LO, Hansman C, Dressler M, Boyd E 1963 Intrauterine growth as estimated from liveborn birth-weight data at 24 to 42 weeks of gestation. Pediatrics 32:793–800
44. Usher RH, McLean F 1969 Intrauterine growth of live-born Caucasian infants at sea level: standards obtained from measurements in 7 dimensions of infants born between 25 and 44 weeks of gestation. J Pediatr 74:901–910
45. Battaglia FC, Lubchenco LO 1967 A practical classification of newborn infants by weight and gestational age. J Pediatr 71:159–163
46. Farquhar JW 1959 The child of the diabetic woman. Arch Dis Child 34:76–96
47. Gellis SS, Hsia DY 1959 The infant of diabetic mother. Am J Dis Child 97:1–41
48. Cornblath M 1961 Infants of diabetic mothers. Pediatrics 28:1024–1026
49. Gruenwald P 1963 Chronic fetal distress and placental insufficiency. Biol Neonate 33:215–265
50. Warkany J, Monroe BB, Sutherland BS 1961 Intrauterine growth retardation. Am J Dis Child 102:249–279
51. Barker DJ, Eriksson JG, Forsen T, Osmond C 2002 Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 31:1235–1239
52. Clifford SH 1954 Post-maturity with placental dysfunction: clinical syndrome and pathologic findings. J Pediatr 44:1–13
53. Boylan P 1990 Induction of labor, complications of labor, and postmaturity. Curr Opin Obstet Gynecol 2:31–35
54. Lees MH 1970 Cyanosis of the newborn infant. Recognition and clinical evaluation. J Pediatr 77:484–498
55. Saugstad OD 2001 Update on oxygen radical disease in neonatology. Curr Opin Obstet Gynecol 13:147–153
56. Appgar V, Holaday DA, James LS, Weisbrot IM, Berrien C 1958 Evaluation of the newborn infant-Second report. JAMA 168:1985–1988
57. Casey BM, McIntire DD, Leveno KJ 2001 The continuing value of the Apgar score for the assessment of newborn infants. N Engl J Med 344:467–471
58. James LS 1975 Fond memories of Virginia Appgar. Pediatrics 55:1–4
59. Saugstad OD 2001 Resuscitation of newborn infants with room air or oxygen. Semin Neonatol 6:233–239
60. Hutchison JH, Kerr MM, Williams KG, Hopkinson WI 1963 Hyperbaric oxygen in the resuscitation of the newborn. Lancet 13:1019–1022
61. Gregory GA, Gooding CA, Phibbs RH, Tooley WH 1974 Meconium aspiration in infants—a prospective study. J Pediatr 85:848–852
62. Carson BS, Losey RW, Bowes WA Jr, Simmons MA 1976 Combined obstetric and pediatric approach to prevent meconium aspiration syndrome. Am J Obstet Gynecol 126:712–715
63. Keenan WJ 1998 The first decade: the neonatal resuscitation program. In: Fanaroff AA, Maxisels MJ, Stevenson DK (eds) Year Book of Neonatal and Perinatal Medicine. Mosby, St. Louis, pp xxix–xxxix
64. Nelson KB 2003 Can we prevent cerebral palsy? N Engl J Med 349:1765–1769
65. Brann AW Jr, Myers RE 1975 Central nervous system findings in the newborn monkey following severe in utero partial asphyxia. Neurology 25:327–338
66. Battin MR, Penrice J, Gunn TR, Gunn AJ 2003 Treatment of term infants with head cooling and mild systemic hypothermia (35.0°C and 34.5°C) after perinatal asphyxia. Pediatrics 111:244–251
67. Avery ME, Mead J 1959 Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 97:517–523
68. Chu J, Clements JA, Cotton E, Klaus MH, Sweet AY, Thomas MA, Tooley WH 1965 The pulmonary hypoperfusion syndrome. Pediatrics. 35:733–742
69. Usher RH 1963 Reduction of mortality from respiratory distress syndrome of prematurity with early administration of intravenous glucose and sodium bicarbonate. Pediatrics 32:966–975
70. Swyer PR 1970 Symposium on artificial ventilation. Summary of conference proceedings. Biol Neonate 16:191–195
71. Northway WH Jr, Rosan RC, Porter DY 1967 Pulmonary disease following respirator therapy of hyaline membrane disease. Bronchopulmonary dysplasia. N Engl J Med 276:357–368
72. Philip AG 1975 Oxygen plus pressure plus time: the etiology of bronchopulmonary dysplasia. Pediatrics 55:44–50
73. Bancalari E, Claire N, Sosenko IR 2003 Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 8:63–71
74. Kuhns LR, Bednarek FJ, Wyman ML, Roloff DW, Borer RC 1975 Diagnosis of pneumothorax and pneumomediastinum in the neonate by transillumination. Pediatrics 56:355–360
75. Donn SM, Kuhns LR 1983 Pediatric Transillumination. Year Book Medical Publishers, Chicago
76. Soll RF, Blanco F 2001 Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress. Cochrane Database Syst Rev (2):CD000144
77. Nelle M, Zilow EP, Linderkamp O 1997 Effects of high-frequency oscillatory ventilation on circulation in neonates with pulmonary interstitial emphysema or RDS. Intensive Care Med 23:671–676
78. Gregory GA, Kitterman JA, Phibbs RH, Tooley WH, Hamilton WK 1971 Treatment of idiopathic respiratory-distress syndrome with continuous positive airway pressure. N Engl J Med 284:1333–1340
79. Kattwinkel J, Fleming D, Cha CC, Fanaroff AA, Klaus MH 1973 A device for administration of continuous positive airway pressure by the nasal route. Pediatrics 52:131–134
80. Gluck L, Kulovich MV 1973 Fetal lung development. Current concepts. Pediatr Clin North Am 20:367–379
81. Adams FH, Desilets DT, Towers B 1967 Control of flow of fetal lung fluid at the laryngeal outlet. Respir Physiol 2:302–309
82. Piper JM, Langer O 1993 Does maternal diabetes delay fetal pulmonary maturity? Am J Obstet Gynecol 168:783–786
83. Piper JM 2002 Lung maturation in diabetes in pregnancy: if and when to test. Semin Perinatol 26:206–209
84. Liggins GC, Howie RN 1972 A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants. Pediatrics 50:515–525
85. Collaborative Group on Antenatal Steroid Therapy 1981 Effects of antenatal dexamethasone administration on the prevention of respiratory distress syndrome. Am J Obstet Gynecol 141:276–286
86. McCarthy M 1994 US recommendations for antenatal corticosteroids. Lancet 343:726

87. National Institute of Child Health and Human Development 1994 Report of the Consensus Development Conference on the Effect of Corticosteroids for Fetal Maturation on Perinatal Outcomes. U.S. Department of Health and Human Services, Washington, DC
88. Ment LR, Oh W, Ehrenkranz RA, Philip AG, Duncan CC, Makuch RW 1995 Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants. *Am J Obstet Gynecol* 172:795–800
89. Pattle RE 1955 Properties, function and origin of the alveolar lining layer. *Nature* 175:1125–1126
90. Clements JA 1957 Surface tension of lung extracts. *Proc Soc Exp Biol Med* 95:170–172
91. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T 1980 Artificial surfactant therapy in hyaline-membrane disease. *Lancet* 1:55–59
92. Merritt TA, Hallman M, Bloom BT, Berry C, Benirschke K, Sahn D, Key T, Edwards D, Jarvenpaa AL, Pohjavuori M, *et al.* 1986 Prophylactic treatment of very premature infants with human surfactant. *N Engl J Med* 315:785–790
93. Corbet AJ, Long WA, Murphy DJ, Garcia-Prats JA, Lombardy LR, Wold DE 1991 Reduced mortality in small premature infants treated at birth with a single dose of a synthetic surfactant. *J Paediatr Child Health* 27:245–249
94. Morley CJ 1989 Prophylactic treatment of premature babies with artificial surfactant (ALEC). *Dev Pharmacol Ther* 13:182–183
95. Speer CP, Robertson B, Curstedt T, Halliday HL, Compagnone D, Gefeller O, Harms K, Herting E, McClure G, Reid M, *et al.* 1992 Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. *Pediatrics* 89:13–20
96. Whitsett JA, Weaver TE 2002 Hydrophobic surfactant proteins in lung function and disease. *N Engl J Med* 347:2141–2148
97. Horbar JD, Wright EC, Onstad L 1993 The Members of the National Institute of Child Health and Human Development Neonatal Research Network. Decreasing mortality associated with the introduction of surfactant therapy: an observational study of neonates weighing 601 to 1300 grams at birth. *Pediatrics* 92:191–196
98. Daily WJ, Klaus M, Meyer HB 1969 Apnea in premature infants: monitoring, incidence, heart rate changes, and an effect of environmental temperature. *Pediatrics* 43:510–518
99. Sinclair JC 1970 The premature baby who “forgets to breathe.” *N Engl J Med* 282:508–509
100. Huch R, Huch A, Lübbers DW 1973 Transcutaneous measurement of blood P_{O_2} (tP_{O_2})—method and application in perinatal medicine. *J Perinat Med* 1:183–191
101. Hay WW Jr, Thilo E, Curlander JB 1991 Pulse oximetry in neonatal medicine. *Clin Perinatol* 18:441–472
102. Kuzemko JA, Paala J 1973 Apnoeic attacks in the newborn treated with aminophylline. *Arch Dis Child* 48:404–406
103. Aranda JV, Gorman W, Bergsteinsson H, Gunn T 1977 Efficacy of caffeine in treatment of apnea in the low-birth-weight infant. *J Pediatr* 90:467–472
104. Firstman R, Talan J 1997 *The Death of Innocents: A True Story of Murder, Medicine, and High-Stake Science*. Bantam Books, New York
105. American Academy of Pediatrics 1992 AAP Task Force on Infant Positioning and SIDS: positioning and SIDS. *Pediatrics* 89:1120–1126
106. Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE 1976 Pharmacologic closure of patent ductus arteriosus in the premature infant. *N Engl J Med* 295:530–533
107. Heymann MA, Rudolph AM, Silverman NH 1976 Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. *N Engl J Med* 295:530–533
108. Elliott RB, Starling MB, Neutze JM 1975 Medical manipulation of the ductus arteriosus. *Lancet* 1:140–142
109. Kitterman JA, Phibbs RH, Tooley WH 1969 Aortic blood pressure in normal newborn infants during the first 12 hours of life. *Pediatrics* 44:959–968
110. So KW, Fok TF, Ng PC, Wong WW, Cheung KL 1997 Randomised controlled trial of colloid or crystalloid in hypotensive preterm infants. *Arch Dis Child Fetal Neonatal Ed* 76:F43–F46
111. Roze JC, Tohier C, Maingueneau C, Lefevre M, Mouzard A 1993 Response to dobutamine and dopamine in the hypotensive very preterm infant. *Arch Dis Child* 69:59–63
112. Gersony WM 1973 Persistence of the fetal circulation: a commentary. *J Pediatr* 82:1103–1106
113. Goetzman BW, Sunshine P, Johnson JD, Wennberg RP, Hackel A, Merten DF, Bartoletti AL, Silverman NH 1976 Neonatal hypoxia and pulmonary vasospasm: response to tolazoline. *J Pediatr* 89:617–621
114. Schreiber MD, Heymann MA, Soifer SJ 1986 Increased arterial pH, not decreased P_{aCO_2} , attenuates hypoxia-induced pulmonary vasoconstriction in newborn lambs. *Pediatr Res* 20:113–117
115. Tolsa JF, Cotting J, Sekarski N, Payot M, Micheli JL, Calame A 1995 Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn. *Arch Dis Child Fetal Neonatal Ed* 72:F184–F187
116. Murphy JD, Rabinovitch M, Goldstein JD, Reid LM 1981 The structural basis of persistent pulmonary hypertension of the newborn infant. *J Pediatr* 98:968–967
117. Kinsella JP, Neish Sr, Ivy DD, Shaffer E, Abman SH 1993 Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide. *J Pediatr* 123:103–108
118. Roberts JD, Polaner DM, Lang P, Zapol WM 1992 Inhaled nitric oxide in persistent pulmonary hypertension of the newborn. *Lancet* 340:818–819
119. Bartlett RH, Andrews AF, Toomasian JM, Haiduc NJ, Gazzaniga AB 1982 Extracorporeal membrane oxygenation for newborn respiratory failure: forty-five cases. *Surgery* 92:425–433
120. O'Rourke PP, Crone RK, Vacanti JP, Ware JH, Lillehei CW, Parad RB, Epstein MF 1989 Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: a prospective randomized study. *Pediatrics* 84:957–963
121. UK Collaborative ECMO Trial Group (Field DJ) 1996 UK collaborative randomized trial of neonatal extracorporeal membrane oxygenation. *Lancet* 348:75–82
122. Winsberg F 1972 Echocardiography of the fetal and newborn heart. *Invest Radiol* 7:152–158
123. Eichenwald H, Kotsevalov O, Fasso LA 1960 The “cloud baby”: an example of bacterial-viral interaction. *Am J Dis Child* 100:161–173
124. Yow EM, Yow MD, Womack GK, Sakuma T, Monzon OT 1958 The management of hospital-acquired staphylococcal infections. *Am Arch Intern Med* 102:948–959
125. Lockhart JD 1972 How toxic is Hexachlorophene? *Pediatrics* 50:229–235
126. Philip AG, Hewitt JR 1980 Early diagnosis of neonatal sepsis. *Pediatrics* 65:1036–1041
127. Sabel KG, Hanson LA 1974 The clinical usefulness of C-reactive protein (CRP) determinations in bacterial meningitis and septicemia in infancy. *Acta Paediatr Scand* 63:381–388
128. Manroe BL, Rosenfeld CR, Weinberg AG, Browne R 1977 The differential leukocyte count in the assessment and outcome of early-onset neonatal group B streptococcal disease. *J Pediatr* 91:632–637
129. Manroe BL, Weinberg AG, Rosenfeld CR, Browne R 1979 The neonatal blood count in health and disease. I. Reference values for neutrophilic cells. *J Pediatr* 95:89–98
130. Nissen MD, Sloots TP 2002 Rapid diagnosis in pediatric infectious diseases: the past, the present and the future. *Pediatr Infect Dis J* 21:605–612
131. McCracken GH Jr 1973 Group B streptococci: the new challenge in neonatal infections. *J Pediatr* 82:703–706
132. Baker CJ 1979 Group B streptococcal infections in neonates. *Pediatr Rev* 1:5–1
133. Benitz WE 2002 Perinatal treatment to prevent early onset group B streptococcal sepsis. *Semin Neonatol* 7:301–314
134. McCracken GH Jr, Mize SG, Threlkeld N 1980 Intraventricular gentamicin therapy in gram-negative bacillary meningitis of infancy. Report of the Second Neonatal Meningitis Cooperative Study Group. *Lancet* 1:787–791
135. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK 2002 Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. *Pediatrics* 110:285–291
136. Chapman RL 2003 Candida infections in the neonate. *Curr Opin Pediatr* 15:97–102
137. Giles JP, Cooper LZ, Krugman S 1965 The rubella syndrome. *J Pediatr* 66:434–437
138. Nahmias AJ 1974 The TORCH complex. *Hosp Pract* 9:65–73
139. Leland D, French ML, Kleiman MB, Schreiner RL 1983 The use of TORCH titers. *Pediatrics* 72:41–43
140. Kumar ML 1991 Human parvovirus B₁₉ and its associated diseases. *Clin Perinatol* 18:209–225
141. Beckerman KP 2002 Mothers, orphans, and prevention of paediatric AIDS. *Lancet* 359:1168–1169
142. Stevenson JK, Oliver TK Jr, Graham CB, Bell RS, Gould VE 1971 Aggressive treatment of neonatal necrotizing enterocolitis: 38 patients with 25 survivors. *J Pediatr Surg* 6:28–35
143. Bisquera JA, Cooper TR, Berseth CL 2002 Impact of necrotizing enterocolitis on length of stay and hospital charges in very low birth weight infants. *Pediatrics* 109:423–428
144. Papile LA, Burstein J, Burstein R, Koffler H 1978 Incidence and evolution of sub-ependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500 gm. *J Pediatr* 92:529–534
145. Pape KE, Blackwell RJ, Cusick G, Sherwood A, Houang MT, Thorburn RJ, Reynolds EO 1979 Ultrasound detection of brain damage in preterm infants. *Lancet* 1:1261–1264
146. Lazzara A, Ahmann P, Dykes F, Brann AW Jr, Schwartz J 1980 Clinical predictability of intraventricular hemorrhage in preterm infants. *Pediatrics* 65:30–34
147. Philip AG, Allan WC, Tito AM, Wheeler LR 1989 Intraventricular hemorrhage in preterm infants: declining incidence in the 1980s. *Pediatrics* 84:797–801
148. Ment LR, Oh W, Ehrenkranz RA, Philip AG, Vohr B, Allan W, Duncan CC, Scott DT, Taylor KJ, Katz KH, *et al.* 1994 Low-dose indomethacin and prevention of intraventricular hemorrhage: a multicenter randomized trial. *Pediatrics* 93:543–550
149. Horbar JD, Badger GJ, Carpenter JH, Fanaroff AA, Kilpatrick S, LaCorte M, Phibbs R, Soll RF, Members of the Vermont Oxford Network 2002 Trends in mortality and morbidity for very low birth weight infants, 1991–1999. *Pediatrics* 110:143–151
150. Lemons JA, Bauer CR, Oh W, Korones SB, Papile LA, Stoll BJ, Verter J, Temprosa M, Wright LL, Ehrenkranz RA, Fanaroff AA, Stark A, Carlo W, Tyson JE, Donovan EF, Shankaran S, Stevenson DK 2001 Very low birth weight outcomes of the National Institute of Child Health and Human Development neonatal research network, January 1995 through December 1996. NICHD Neonatal Research Network. *Pediatrics* 107:E1
151. Rhine WD, Ashwal S, Holshouser B, D'Arceuil HE, Van Houten JP, Contag CH, Benaron DA, Stevenson DK 1997 Non-invasive monitoring: the next generation. In: Fanaroff AA, Maisels MJ, Stevenson DK (eds) *Yearbook of Neonatal and Perinatal Medicine*, Mosby, St. Louis, pp xvii–xlvii
152. Smith LE 2002 Pathogenesis of retinopathy of prematurity. *Acta Paediatr Suppl* 91:26–28
153. Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results 1988 Cryotherapy for Retinopathy of Prematurity Cooperative Group. Preliminary results. *Pediatrics* 81:697–706

154. Behrman RE, Babson GS, Lessel R 1971 Fetal and neonatal mortality in white middle class infants: mortality risks by gestational age and weight. *Am J Dis Child* 121:486–489
155. Drillien CM 1967 The long-term prospects for babies of low birth weight. *Br J Hosp Med* 1:937–944
156. Templeton A, Morris JK 1998 Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. *N Engl J Med* 339:573–577
157. Hansen M, Kurinczuk JJ, Bower C, Webb S 2002 The risk of major birth defects after intracytoplasmic sperm injection or in vitro fertilization. *N Engl J Med* 346:725–730
158. Schieve LA, Meikle SF, Ferre C, Peterson HB, Jeng G, Wilcox LS 2002 Low and very low birthweight in infants conceived with use of assisted reproductive technology. *N Engl J Med* 346:731–737
159. Usher RH 1971 Clinical implications of perinatal mortality statistics. *Clin Obstet Gynecol* 14:885–925
160. Philip AG, Little GA, Polivy DR, Lucey JF 1981 Neonatal mortality risk for the eighties: the importance of birth weight/gestational groups. *Pediatrics* 68:122–130
161. Butterfield LJ 1983 The impact of regionalization on neonatal outcome. In: Smith GF, Vidyasagar D (eds) *Historical Review and Recent Advances in Neonatal and Perinatal Medicine*, Vol 2. Mead Johnson Nutritional Division, Evansville, pp 107–124
162. Butterfield LJ 1993 Historical perspectives of neonatal transport. *Pediatr Clin North Am* 40:221–239
163. Lubchenco LO, Butterfield LJ, Delaney-Black V, Goldson E, Koops BL, Lazotte DC 1989 Outcome of very low birth weight infants: does antepartum versus neonatal referral have a better impact on mortality, morbidity or long-term outcome? *Am J Obstet Gynecol* 160:539–545
164. DeVries RG 1979 Responding to consumer demand: a study of alternative birth centers. *Hosp Prog* 60:48–51, 68
165. Frank JE, Rhodes TT, Edwards WH, Darnall RA, Smith BD, Little GA, Baker ER, Stys SJ, Flanagan VA 1999 The New Hampshire Perinatal Program: twenty years of perinatal outreach education. *J Perinatol* 19:3–8
166. Barnett ER, Leiderman PH, Grobstein R, Klaus M 1970 Neonatal separation: the maternal side of interactional deprivation. *Pediatrics* 45:197–205
167. Klaus MH, Kennell JH 1970 Mothers separated from their newborn infants. *Pediatr Clin N Am* 17:1015–1037
168. Klaus MH, Kennell JH 1982 *Parent-Infant Bonding*, 2nd Ed. C.V. Mosby, St. Louis
169. Brazelton TB 1973 *Neonatal Behavioral Assessment Scale*. JB Lippincott, Philadelphia
170. Halamek LP 2003 Prenatal consultation at the limits of viability. *Neoreviews* 4:e153–e156
171. Meier PP, Brown LP 1996 State of the science. Breastfeeding for mothers and low birth weight infants. *Nurs Clin North Am* 31:351–365
172. Whitelaw A, Sleath K 1985 Myth of the marsupial mother: home care of very low birth weight babies in Bogota, Colombia. *Lancet* 1:1206–1208
173. Anderson GC 1991 Current knowledge about skin-to-skin (kangaroo) care for preterm infants. *J Perinatol* 11:216–226
174. Lesser AL 1963 Phenylketonuria and the Guthrie test. *Pediatrics* 32:940
175. Fisch RO, Anthony BF, Bauer H, Bruhl HH 1968 The effect of antibiotics on the results of the Guthrie test given to phenylketonuric patients. *J Pediatr* 73:685–689
176. Dussault JH, Coulombe P, Laberge C, Letarte J, Guyda H, Khoury K 1975 Preliminary report on a mass screening program for neonatal hypothyroidism. *J Pediatr* 86:670–674
177. Wilcken B, Wiley V, Hammond J, Carpenter K 2003 Screening newborns for inborn errors of metabolism by tandem mass spectrometry. *N Engl J Med* 348:2304–2312
178. Queenan JT 2002 Rh-disease: a perinatal success story. *Obstet Gynecol* 100:405–406
179. Kappas A, Drummond GS, Valaes T 2001 A single dose of Sn-mesoporphyrin prevents development of severe hyperbilirubinemia in glucose-6 phosphate dehydrogenase-deficient newborns. *Pediatrics* 108:25–30
180. Maisels MJ, Kring E 1998 Length of stay, jaundice and hospital readmission. *Pediatrics* 101:995–998
181. Yamanouchi I, Yamauchi Y, Igarashi I 1980 Transcutaneous bilirubinometry: preliminary studies of non-invasive transcutaneous bilirubin meter in Okayama National Hospital. *Pediatrics* 65:195–202
182. Bhutani VK, Johnson L, Sivieri EM 2001 Predictive ability of a predischARGE hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. *Pediatrics* 103:6–14
183. Stevenson DK, Fanaroff AA, Maisels MJ, Young BW, Wong RJ, Vreman HJ, MacMahon JR, Yeung CY, Seidman DS, Gale R, Oh W, Bhutani VK, Johnson LH, Kaplan M, Hammerman C, Nakamura H 2001 Prediction of hyperbilirubinemia in near-term and term infants. *Pediatrics* 108:31–39
184. Brown AK, Johnson L 1996 Loss of concern about jaundice and the re-emergence of kernicterus in full term infants in the era of managed care. In: Fanaroff AA, Klaus M (eds) *Yearbook of Neonatal and Perinatal Medicine*. Mosby-Year Book, St. Louis, pp xvii–xxviii
185. Dobbs RH, Cremer RJ 1975 Phototherapy. *Arch Dis Child* 50:833–836
186. Lucey J, Ferreira M, Hewitt J 1968 Prevention of hyperbilirubinemia of prematurity by phototherapy. *Pediatrics* 41:1047–1054
187. Gale R, Dranitzki Z, Dollberg S, Stevenson DK 1990 A randomized controlled application of the Wallaby phototherapy system compared with standard phototherapy. *J Perinatol* 10:239–242
188. Seidman DS, Moise J, Ergaz Z, Laor A, Vreman HJ, Stevenson DK, Gale R 2000 A new blue light-emitting phototherapy device: a prospective randomized controlled study. *J Pediatr* 136:771–774
189. American Academy of Pediatrics; American College of Obstetricians and Gynecologists 2002 Care of the neonate. In: *Guidelines for Perinatal Care*, 5th Ed. American Academy of Pediatrics, Elk Grove Village
190. Erenberg A, Lemons J, Sia C, Trunkel D, Ziring P 1999 Newborn and infant hearing loss: detection and intervention. American Academy of Pediatrics. Task Force on Newborn and Infant Hearing, 1998–1999. *Pediatrics* 103:527–530
191. Colletti RB 1983 Hospital-based rental programs to increase car seat usage. *Pediatrics* 71:771–773
192. Bass JL, Mehta KA, Camara J 1993 Monitoring premature infants in car seats: implementing the American Academy of Pediatrics policy in a community hospital. *Pediatrics* 91:1137–1141
193. Pearson HA 1989 The Centennial History of the American Pediatric Society 1888–1988: A Century of Progress in Child Health. Yale University Print Service, New Haven, CT
194. Butterfield LJ 1999 The AAP Section on Perinatal Pediatrics 1974–1999. In: Fanaroff AA, Maisels MJ, Stevenson DK (eds) *Year Book of Neonatal and Perinatal Medicine*. Mosby, St. Louis, pp xvii–xxiv
195. Robertson AF 2003 Reflections on errors in neonatology: I. The “hands-off” years, 1920 to 1950. *J Perinatol* 23:48–55
196. Robertson AF 2003 Reflections on errors in neonatology: II. The “heroic” years, 1950 to 1970. *J Perinatol* 23:154–161
197. Robertson AF 2003 Reflection on errors in neonatology: III. The “experienced years,” 1970 to 2000. *J Perinatol* 23:240–249
198. Vengusamy S, Pildes RS, Raffensperger JF, Levine HD, Cornbath M 1969 A controlled study of feeding gastrostomy in low birth weight infants. *Pediatrics* 43:815–820
199. Greenspan JS, Wolfson MR, Rubinstein SD, Shaffer TH 1990 Liquid ventilation of human preterm neonates. *J Pediatr* 117:106–111
200. Horbar JD, Rogowski J, Plsek PE, Delmore P, Edwards WH, Hocker J, Kantak AD, Lewallen P, Lewis W, Lewit E, McCarroll CJ, Mujsec D, Payne NR, Shiono P, Soll RF, Leahy K, Carpenter JH 2001 Collaborative quality improvement for neonatal intensive care. NIC/Q Project Investigators of the Vermont Oxford Network. *Pediatrics* 107:14–22
201. Horbar JD, Plsek PE, Leahy K 2003 NIC/Q 2000: establishing habits for improvement in neonatal intensive care units. *Pediatrics* 111:e397–e410
202. Wirtschafter DD, Powers RJ 2004 Organizing regional perinatal quality improvement: global considerations and a case study of a local implementation. *Neoreviews* 5:e50–e59
203. Soll RF, Andruscavage L 1999 The principles and practice of evidence-based neonatology. *Pediatrics* 103:e215–e224
204. McCaffrey A, Kay MA, Contag CH 2003 Advancing molecular therapies through in vivo bioluminescent imaging. *Mol Imaging* 2:75–86
205. Contag CH, Stevenson DK 2001 In vivo patterns of heme oxygenase-1 transcription. *J Perinatol* 21:S119–S124
206. Mitchell-DiCenso A, Guyatt G, Marrin M, Goeree R, Willan A, Southwell D, Hewson S, Paes B, Rosenbaum P, Hunsberger M, Baumann A 1996 A controlled trial of nurse practitioners in neonatal intensive care. *Pediatrics* 98:1143–1148
207. Paoletti LC, Madoff LC 2002 Vaccines to prevent neonatal GBS infection. *Semin Neonatol* 7:315–323
208. Kaviani A, Perry TE, Dzakovic A, Jennings RW, Ziegler MM, Fauza DO 2001 The amniotic fluid as a source of cells for fetal tissue engineering. *J Pediatr Surg* 36:1662–1665
209. Donati V, Arena S, Capilli G, Carrera G, Ciralli F, Liberatore A 2001 Reparation of a severe case of aplasia cutis congenita with engineered skin. *Biol Neonate* 80:273–276
210. Brune T, Garritsen H, Hentschel R, Louwen F, Harms E, Jorch G 2003 Efficacy, recovery, and safety of RBCs from autologous placental blood: clinical experience in 52 newborns. *Transfusion* 43:1210–1216